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Cardiovascular diseases and their long term consequences constitute serious health 
and economic burdens. Although promising new therapeutic approaches to ameliorate 
the detrimental consequences have been introduced, there is still no therapy that would 
lead to a therapeutically efficient replacement of lost cardiomyocytes (CMs), e.g. after a 
myocardial infarction. CMs can be reliably generated from pluripotent stem cells, 
including embryonic and induced pluripotent stem cells. Parthenogenetic stem cells 
(PSCs) have recently been introduced as an alternative, attractive pluripotent stem cell 
entity. PSCs generated from pharmacologically activated unfertilized oocytes contain 
only maternal chromosomes, and show a growth and differentiation behavior similar to 
embryonic stem cells (ESCs). The unique chromosomal constitution of PSCs makes 
them largely haploidentical, creating the possibility for immunological matching.  
In this study we demonstrated that transgenic major histocompatibility complex (MHC)-
haploidentical PSCs (H-2d/d) can be generated carrying a neomycin resistance gene 
(NeoR) transcribed under the control of the CM-restricted alpha myosin heavy chain 
(MYH6) promoter for antibiotic selection of PSC-CMs. Differentiation and 
cardiomyocytes purification could be achieved at a large scale in suspension culture 
spinner flasks. PSC-derived non-myocytes (NM) express MHC-I which was significantly 
upregulated after interferon gamma (IFNγ) stimulation. PSC-derived CM did not express 
MHC-I and MHC-II under basal conditions, but were up-regulated after IFNγ treatment. 
Expression of co-stimulatory molecules (CD40, CD80 and CD86) was not evident in 
PSC-derivatives under baseline or IFNγ stimulated conditions. PD-L1 expression was 
upregulated after IFNγ stimulation. In vitro immune cell proliferation assays showed that 
PSC-CM and PSC-NM had strong effect on lymphocyte activation, while PSC-EHM had 
negligible effect on lymphocyte stimulation. Implantation of PSC-CM under the kidney 
capsule suggested enhanced survival under MHC-matching. In conclusion, this study 
provides insight into the immunological properties of PSC-derived cardiomyocytes and 





PSC  parthenogenetic stem cells 
ESC  embryonic stem cells 
iPSC  induced pluripotent stem cells 
maGSC male germline stem sells 
LIF  leukemia inhibitory factor 
EB  embryoid body 
EGFP  enhanced green fluorescence protein 
MHC  major histocomptability complex 
mHC  minor histocompatibility complex 
HLA  human leukocyte antigen 
CD  cluster of differentiation 
ICAM  intracellular adhesion molecule 
GvHD  graft vs host disease 
APC  antigen presenting cells 
MSC  mesenchymal stem cells 
CTL  cytotoxic T-lymphocyte 
TCR  T-cell receptor 
IL  interleukins 
IFN  interferons 
IFNγ  interferon gamma 
IFNGR interferon gamma receptor 
GAS  interferon gamma activation site 




IRF  interferon response factor 
MIG  monokine induced interferon gamma 
ISRE  interferon stimulated response element 
TGFβ  transforming growth factor beta 
IDO  indoleamine 2, 3-dioxygenase 
TAP  transporter associated antigen processing 
NK cells natural killer cells 
DMAP  6-dimethylaminopurine 
SSEA-1 stage specific embryonic antigen 1 
MI  metaphase I 
PB  polar body 
EHM  engineered heart muscle 
CM  cardiomyocytes 
NM  non myocytes 
OD  optical density 
PCR  polymerase chain reaction 
MEFs  mouse embryonic fibroblasts 
PBS  phosphate buffered saline 
DMEM Dulbecco´s modified eagle´s medium 
FCS  fetal calf serum 
NEAA  non essential aminoacids 
DMSO dimethyl sulphoxide 
NeoR  neomycin resistance 
EDTA  ethylenediaminetetraacetic acid 




BSA  bovine serum albumin 
PD-1  programmed death 1 
PD-L1  programmed death ligand-1 
MACS  magnetic activated cell sorting 
MEM  minimal essential medium 
GAPDH glyceraldehyde 3-phosphate-dehydrogenase 
G-418  geneticin 
BDM  2, 3-butanedione 2-monoxime 
DAPI  4’, 6’-diamidino-2-phenylindole 
αMyHC alpha myosin heavy chain (MyH6) 
B2M  beta 2-microglobulin 
IgG  immunoglobulin G  
CDCs  cardiosphere derived cells 
CFSE  carboxyfluorescein succinimidyl ester 
NKT cells natural killer T cells 





1.1 Cardiovascular diseases and cardiac tissue engineering 
Patients commonly lose approximately 50 grams, i.e. 10% of the total heart muscle 
mass upon myocardial infarction (Vunjak-Novakovic et al., 2010). This loss in contractile 
cells is for the most part irreversible and thus leads to contractile failure of the heart. 
Heart failure is a leading cause of death throughout the world (Doppler et al., 2013; 
Sanchez et al., 2006). In light of an increasing life expectancy and incidence of 
cardiovascular insults with age and the increasing effectiveness of acute medical 
interventions leading to the stabilization of hemodynamics without any palpable 
remuscularization, there is a pressing need to develop novel therapeutics to regenerate 
or biologically repair the failing heart. 
Drug and device therapies (e.g. cardiac resynchronization, left ventricular assist 
devices) have improved the prognosis of heart failure patients (Katz, 2008). However, in 
end stage heart failure, heart transplantation remains the only causal therapy (Agnetti et 
al., 2015). Due to the shortage of organ donors (~300 heart transplants are performed 
annually in Germany), heart transplantation will remain an option only for a few selected 
heart failure patients and cannot be considered as a therapeutic solution for the 
anticipated heart failure epidemic. In vitro engineered heart muscle is thus developed to 
overcome this limitation and provide ideally functional and immunologically matched 
allografts.   
Tissue engineering combines cells, biomaterials and growth factors to generate 
functional three-dimensional (3D) tissue outside of the body. Cardiac regeneration using 
engineered tissue requires the seamless integration of bioengineered structure into the 
myocardium. Structural, functional and immunological properties of the engineered 
grafts have to be matched with the recipient to achieve this (Karikkineth and 
Zimmermann, 2013; Soler-Botija et al., 2012; Ye et al., 2013). 
The heart is a highly complex organ with contractile, conductive and vascular systems 




functional organs formed in the human body and mechanically the most dynamic one 
(Buckingham et al., 2005). Cardiomyocytes form a three-dimensional network that 
propagates electrical signals across cellular junctions to trigger mechanical contractions 
and pump the blood (Severs, 2000). However cardiomyocytes make up for only 25-35% 
of the cells in an adult heart while endothelial cells, fibroblasts and smooth muscle cells 
represent the majority of the cardiac cell population (Bergmann et al., 2015; Pinto et al., 
2016). 
Several groups have reported promising results with various methods for constructing 
cardiomyocytes seeded patches (Ye et al., 2013).The first engineered cardiac muscle 
with palpable contractile performance was generated from chick embryo 
cardiomyocytes in collagen hydrogels (Eschenhagen et al., 1997) by an adaptation of a 
three-dimensional culture format for biophysical studies of chick embryo fibroblasts 
(Kolodney and Elson, 1993). This protocol could be successfully adopted to the rat 
model and further optimized by the introduction of MatrigelTM to enhance 
cardiomyocytes spreading and mechanical loading and to improve force development 
(Zimmermann et al., 2000). Function and geometry could subsequently be optimized by 
adding non-myocytes (Naito et al., 2006b) and fusion of individual tissue units 
(Zimmermann et al., 2006). Most recently combined electromechanical stimulation was 
introduced to further advance tissue maturation (Godier-Furnemont et al., 2015). This 
engineered heart muscle (EHM) technology was also demonstrated to be applicable to 
mouse and human pluripotent stem cell derived cardiomyocytes (Didie et al., 2013; 
Soong et al., 2012; Tiburcy et al., 2014). Alternative tissue engineering technologies 
include cell sheet engineering in which three dimensional tissues are formed by layering 
cell sheets without any additional scaffold materials (Shimizu et al., 2002).   
Implantation of EHM on chronically scarred (Zimmermann et al., 2006) or acutely 
injured (Didie et al., 2013) myocardium was feasible and demonstrated therapeutic 
efficacy, i.e., enhance systolic thickening of the infarct region. The therapeutic effect 
was most pronounced in rats with overt heart failure (Zimmermann et al., 2006). In a 
recent xenograft study of human EHM in immune compromised rats (RNU-rats) long-




ischemia/reperfusion injury could be demonstrated (Riegler et al., 2015). A concurrent 
finding was strong vascularization of the primarily avascular grafts upon implantation. A 
surprising observation already in an earlier syngeneic implantation model was strong 
immune rejection (Zimmermann et al., 2002). Hence, immune suppression had to be 
applied and was used successfully in the follow-up allograft study (Zimmermann et al., 
2006). To address the immunological complication also in an allograft setting, 
parthenogenetic stem cells were developed and tested in mice with matching and 
mismatching H-2 composition (Didie et al., 2013). The results of this study were in line 
with the hypothesis that haploidentical parthenogenetic stem cells would represent more 
generic donor lines for cell based tissue repair because of their less complex variation in 
the MHC locus (Doulatov and Daley, 2013). 
1.2 Stem cell sources 
A human left ventricle consists of 6 ±1.8 x 109 myocyte nuclei which varies depending 
on the age of the individual (Olivetti et al., 1991). After a myocardial infarction 
approximately one billion cardiomyocytes (Murry and Keller, 2008) are lost, that have to 
be replaced in a successful tissue engineering cardiac repair approach. Several animal 
studies showed a successful engraftment of immature cardiomyocytes into the adult 
heart (Delcarpio and Claycomb, 1995; Koh et al., 1993; Koh et al., 1995; Muller-Ehmsen 
et al., 2002; Rubart et al., 2003). Limiting factors for such a therapeutic approach are 
low cell retention and the availability of cardiomyocytes at clinical scale and quality. 
Pluripotent stem cells could overcome the limited provision of cardiomyocytes if their 
differentiation into functionally competent cardiomyocytes can be ensured. Large efforts 
have been made to develop strategies for the differentiation of different pluripotent stem 
cell types into cardiomyocytes. Embryonic stem cells constitute the prototypic 
pluripotent stem cell type. Mouse embryonic stem cells (ESCs) appear to be derived 
preferentially from the early inner cell mass (Evans and Kaufman, 1981). At this stage, 
murine ESCs rely on the presence of leukemia inhibitory factor (LIF) to maintain 
pluripotency. In contrast, human embryonic stem cells appear to be largely derived from 
the epiblast and thus dependent on basic fibroblast growth factor (bFGF) signaling to 




human and murine ESCs exhibit comparable differentiation potential. Here it is 
important to note that differences in the extent of cardiac differentiation are often 
reported for different ESC lines (Hannes et al., 2015; Sepac et al., 2012). 
Mainly owing to ethical concerns related to the inevitable destruction of a potentially 
viable embryo during ESC generations, alternative pluripotent cell sources have been 
sought for. These include parthenogenetic stem cells (PSC) (Didie et al., 2013), male 
germline stem cells (maGSCs) (Guan et al., 2006) and induced pluripotent stem cells 
(iPSC) (Takahashi and Yamanaka, 2006) (Figure 1).  
Embryonic stem cells (ESCs) are highly susceptible to directed differentiation towards 
the cardiomyocyte lineage (Burridge et al., 2015; Kattman et al., 2011; Lian et al., 2013; 
Zhu et al., 2011)  Induced pluripotent stem cells have similar properties, but appear 
more variable in outcome (Wright et al., 2014). Although less studied than ESC and 
iPSC, there is clear evidence for similar cardiomyogenic potential in ESC and PSC 
(Didie et al., 2013).                             
                        
Figure 1: Generation of stem cells for cardiac tissue engineering. The inner cell mass of embryonic 
and parthenogenetic blastocysts can be harvested to establish pluripotent stem cells from its outgrowths. 
Male germ line stem cells and induced pluripotent stem cells require selection in culture or 




1.3 Cardiac differentiation of stem cells 
It has been demonstrated that the formation of ESC aggregates induces multicellular 
interactions and thus promotes their differentiation into the derivatives of all three germ 
layers (Wobus and Boheler, 2005). This property is exploited commonly for the 
induction of cardiac differentiation in mouse ESCs. ESC aggregates are generally 
prepared via the formation of suspended spherical aggregates called embryoid bodies 
(EB).  
There are two major conventional methods for the preparation of EBs. One is a hanging 
drop method and the other is a suspension culture method. In case of the hanging drop 
method, the droplets of ESC suspension are hanged from the lid of culture dishes for 
several days and then an EB is formed in each droplet. In this method, the size of EBs 
can be controlled by the cell concentration in the suspension. It has been shown that 
the direction and efficiency of ESC differentiation significantly depend on the size of EBs 
(Ng et al., 2005; Wobus et al., 1991). Therefore, the hanging drop method is 
advantageous to prepare size-controlled EBs for the efficient and reproducible ESC 
differentiation into a specific lineage. On the other hand, the hanging drop method is 
time consuming and labor-intensive and thus disadvantageous in the mass preparation 
of cardiomyocytes.  
In case of the suspension culture method, ESCs are cultured in non-adhesive culture 
dishes for several days and then EBs are forming randomly and spontaneously. In this 
method, a large number of EBs can be easily prepared. In contrast, however, the size of 
EBs is not controlled and thus the differentiation efficiency and reproducibility becomes 
much lower than the case of hanging drop method (Kurosawa, 2007). For the 
generation of large number of cardiomyocytes, more cost-effective culture methods are 
needed. Several research groups started to develop scalable culture methods for the 
mass preparation of size-controlled EBs, such as multiwell plates (Kim et al., 2007), 
microwell substrates (Khademhosseini et al., 2006; Mohr et al., 2006), patterned culture 
plates (Bauwens et al., 2008; Sasaki et al., 2009) and rotary suspension culture in 




Selecting bioreactors for stem cell expansion and differentiation mainly depends on 
whether the cells are adherent, suspension grown as single cells or aggregates for EB 
formation (King and Miller, 2007). In addition, bioreactors have significant advantages 
over static suspension culture which are as follows: scale up of expansion and 
differentiation of ES cells, less labor-intensive, less space requirement and the ability to 
monitor and control critical culture parameters (i.e. pH, dissolved oxygen, glucose 
consumption and lactic acid production) (Kempf et al., 2014). In this study we have 
chosen spinner flask type bioreactors for the differentiation of PSC into cardiomyocytes 
in large scale. 
Spinner flasks have been developed, as promising in vitro systems for stem cell 
expansion, EB cultivation and differentiation of ES/iPS cells into specific cell types 
(Serra et al., 2009). Spinner flasks provide attractive benefits due to their simple design, 
scalable configuration, the possibility for culture of cells in aggregates or microcarriers 
(Abranches et al., 2007) and ease of continuous monitoring for tight regulation of the 
culture environment (e.g. O2 tension, pH, shear forces, medium exchange rate) 
(Zandstra et al., 2003). The rotation of hanging pendulum in spinner flasks results in the 
formation of large ES cells aggregates within a few days (Schroeder et al., 2005). The 
scaling-up is generally simple because of improved homogenous mixing of cell 
suspension achieved by stirring. Numerous culture parameters for this system have 
been optimized including the agitation rate, cell concentration and medium 
compositions. Consequently, an optimal medium velocity promoting the suitable shear 
stress for the cell type being cultured is also important (Fok and Zandstra, 2005). 
 
For clinical uses, pluripotent stem cells must be propagated and efficiently differentiated 
into cardiomyocytes which should be highly purified before transplantation to prevent 
the development of tumors derived from contaminating pluripotent stem cells (Lin et al., 
2010). Several biochemical substances, such as retinoic acid (Wobus et al., 1997), 
ascorbic acid (Takahashi et al., 2003), nitric oxide (Kanno et al., 2004), Bone 




2006a) and activin A (Laflamme et al., 2007), were found to promote cardiac 
differentiation of ESCs. 
With respect to the purification of ESC-derived cardiomyocytes, Klug et al. developed a 
transgenic purification method using antibiotic-resistant gene, which was designed to  
be expressed in differentiated cardiomyocytes; cardiomyocytes purities of 99% can be 
achieved with this approach (Klug et al., 1996). Similar genetic purification methods 
were developed later by the use of reporter genes such as enhanced green 
fluorescence protein (EGFP) which yields around 98% pure cardiomyocytes (Anderson 
et al., 2007; Hidaka et al., 2003). Cardiomyocytes up to 99% purity was also obtained 
by transgene-free metabolic selection after differentiation of stem cells (Tohyama et al., 
2013). Enriched populations of functional cardiomyocytes with up to 88% purity can also 
be obtained by discontinuous percoll gradient centrifugation (E et al., 2006). 
1.4 Major histocompatibility complex and transplantation immunology 
Transplantation of cells, tissues and organs between genetically non-identical 
individuals results in most cases in the development of an immune response towards 
the graft and consequently to graft destruction which poses a pivotal challenge for 
translating cell based therapeutics into a clinical application. Organ rejection is primarily 
targeted at proteins, so called alloantigens presented by donor cells at the cell 
membrane (Bradley et al., 2002). There are three distinct classes of alloantigens: (1) the 
major histocompatibility complex antigens (MHC), (2) the minor histocompatibility 
complex (mHC) antigens and (3) the ABO blood group antigens. The most rapid and 
acute rejection occurs due to failure to properly match donor and recipient MHC alleles 
(Drukker, 2004). 
Human MHC molecules are known as human leukocyte antigen (HLA) and mouse as H-
2, for histocompatibility 2. The HLA genes are located on human chromosome 6.The 
mouse H-2 genes are located on mouse chromosome 17 (Figure 2). The MHC genes 
are traditionally divided into three classes: the MHC class I and class II genes, which 




group of genes encoding molecules with important immune functions and others with no 
known immune function. Another immunologically highly relevant gene, the gene 
encoding b2-microglobulin lies outside the MHC coding region, on mouse chromosome 
2. All the other genes encoding chains of the class I and class II MHC molecules are 
present in several different copies within the MHC genomic region and each cell 
expressing them displays several different MHC molecules (Moussa et al., 2012). The 
peptide antigen-presenting MHC molecules are known as classical MHC molecules. 
There are also structurally related molecules of both classes that do not function in the 
presentation of peptide antigens to T-cells: these are known as non-classical MHC 
molecules. The classical MHC molecules are present in more than 500 different 
variants. 
 
Figure 2: MHC polymorphism on mouse chromosome 17. Distribution of MHC- molecules on mouse 
chromosome 17. Figure adapted from Moussa et al. (2012). 
The MHC antigens were originally recognized for their role in initiating T-cell responses 
that lead to the rejection of transplanted tissue. The MHC class I antigens are 
traditionally associated with the activation of CD8+ cytotoxic T-lymphocytes (CTLs), 
whereas MHC class II antigens are recognized by CD4+ helper T-lymphocytes (TH) 




It is well established that HLA compatibility determines kidney and bone marrow 
allograft survival (Picascia et al., 2014). Cardiac rejection can be either hyper acute, 
acute or chronic which attack two different compartments of the heart. (1) Hyper acute 
rejection is mediated by preformed antibodies in the recipient directed against donor cell 
antigen’s (Dronavalli et al., 2015). (2) Acute rejection is defined by interstitial 
mononuclear cell infiltrates with myocyte damage. (3) Chronic rejection is mediated by 
constant low grade inflammation of the vasculature with similarities to classical 
arteriosclerosis and subsequent organ failure (Kaul et al., 2015).  
The behavior of alloantigen specific T-cells in response to heart, skin and islet allografts, 
showed marked differences in the susceptibility of different organs to rejection and 
resistance to the induction of tolerance. It could be demonstrated that CD8+ T-cells are 
dependent on CD4+ T-cells during cardiac allograft rejection in contrast to skin and islet 
allografts (Jones et al., 2001). It has also been demonstrated that increasing the mass 
of transplanted organs prolonged graft survival (Sun et al., 1995).  
The expression of MHC antigens in various organs and tissues was determined 
intensively in animals and humans. Several groups show that expression of class II 
antigens is increased in rejected organs and in tissues undergoing autoimmune injury, 
in viral disease and in inflammatory conditions (Isobe et al., 1992). High expression of 
MHC-I on the myocardium was observed in 75% of cardiac biopsies from patients who 
had received cardiac transplantation (Rose et al., 1986). However, in most studies 
MHC-expression was analyzed in histological samples of whole hearts including non- 
cardiomyocytes. Cardiac interstitial cells such as endothelial and dendritic cells can 
serve as non-professional and professional antigen presenting cells respectively. Within 
the myocardium they express high levels of MHC I, MHC II and Intracellular adhesion 
molecule 1 (ICAM-1) (Karabekian et al., 2011). Native adult cardiomyocytes express 
low levels of MHC I antigens (MHC K and D in mice) and do not express detectable 
levels of MHC II antigens (MHC IA and IE in mice) (Isobe et al., 1992). 
Theoretically HLA-A, B, C antigen expression should be on the membranes of 




no expression of MHC class I antigen on the cardiomyocyte sarcolemma. Whether the 
absence of MHC antigen expression is a methodological problem because the antigen 
density is below the sensitivity of staining or is a true absence of these proteins is 
unclear (Hufnagel and Maisch, 1991). Interestingly allogeneic cardiosphere derived 
cells appear less immunogenic in vivo and can survive in the infarcted myocardium for 3 
weeks in order to stimulate endogenous reparative and regenerative pathways 
(Malliaras et al., 2012). 
Cardiac cells are able to upregulate MHC-antigens after viral infection. Huber et.al 
showed that two types of CD8+ T-cells infiltrate the myocardium during coxsackievirus 
B3-induced myocarditis. One type expresses αβ T-cell receptors and represents the 
classical antigen specific T-cells which are MHC antigen restricted and abundant in 
peripheral lymphoid tissues. The second type expresses γδ T-cell receptors, these cells 
are usually a minor component of peripheral lymphoid tissues, but tend to accumulate in 
inflammatory lesions. These lymphocytes recognize antigen independently of MHC 
molecules through Fas dependent apoptosis (Huber, 2000). 
Apart from MHC antigens, minor histocompatibility antigens can also trigger graft versus 
host disease (GvHD) (Goulmy, 1997; Korngold and Sprent, 1983). A number of minor 
antigens have now been described and characterized (Simpson et al., 2002). Even if 
the stem cells are from an autologous source, it is possible that so called autoantigens 
are presented followed by an immune response (Boyd et al., 2005). 
1.5 The allorecognition pathways 
The allorecognition pathways are mainly mediated by professional antigen presenting 
cells (APCs) and T-cells which can be divided into the direct and the indirect 
allorecognition pathways. In the direct allorecognition pathway donor derived APCs, 
contained within the graft, move to near lymph nodes where they interact with host 
CD4+ and CD8+ T-cells. Due to the expression of foreign MHC class II molecules 
resident CD4+ and CD8+ T-cells become activated and elicit an immune response 




In the indirect allorecognition pathway professional APCs of the host engulf antigens 
derived from transplanted cells which became necrotic or apoptotic. These MHC 
antigens are subsequently presented to host CD4+ and CD8+ T-cells in draining lymph 
nodes inducing immune rejection against somatic cells which display these antigens. In 
the context of stem cell derived cardiac cell replacement therapies mainly the indirect 
pathway would be involved since preferably pure cell population without the presence of 
APCs would be transplanted. 
                                
Figure 3: Direct and indirect T-cell allorecognition pathways. A. In direct allorecognition, T-cells 
recognize intact allogeneic MHC molecules together with the bound antigen on the surface of donor 
APCs in the graft. B. In indirect allorecognition, alloantigens are recognized as linear peptides in the 
milieu of recipient MHC class II molecules after they have been processed and presented by recipient 
APCs. Figure adapted from Bradley et al. (2002). 
1.6 Stem cell immunology 
Many stem cells express no or only low levels of MHC antigens and have been 
considered to be immune privileged or lacking the ability to induce an immune 
response. In fact, ESCs and mesenchymal stem cells (MSCs) have been considered as 
prototypes for immune privileged cells for cell transplantation studies (Menendez et al., 




Using standard flow cytometry, neither MHC class I nor MHC class II complexes were 
detected on the cell surface of mESCs (Magliocca et al., 2006; Tian et al., 1997). 
However, even very few MHC class I complexes on target cells are sufficient to induce 
transient calcium signaling and killing activity in CTLs (Brower et al., 1994) and the 
ability of CTLs to kill mESCs was shown in vitro (Dressel et al., 2009).  
The presence of MHC class I molecules on mESCs was also demonstrated utilizing 
lacZ-inducible, antigen/MHC class I specific T-cell hybridomas (Abdullah et al., 2007). 
These T-cell hybridomas had a lacZ reporter gene under control of the IL-2 promoter. 
Following T-cell receptor (TCR)-dependent activation upon co-culture with αPIG ESCs, 
the T-cell hybridomas expressed β-galactosidase. In addition, T-cell mediated 
responses against mESCs were demonstrated in vivo (Boyd and Wood, 2009; Dressel 
et al., 2009; Robertson et al., 2007; Wu et al., 2008).  
Contradictory data was published regarding the ability of mESCs to respond to IFNγ 
signaling. One group reported that the expression of MHC class I molecules was not 
enhanced after IFNγ treatment, neither on transcript nor on protein level (Abdullah et al., 
2007; Nussbaum et al., 2007; Tian et al., 1997). Another group reported that MHC class 
I molecule expression increased after IFNγ treatment in mESCs (Bonde and Zavazava, 
2006). Likewise, it remains uncertain how the expression of MHC class I molecules 
changes upon differentiation of mESCs. 
Lampton et al. have examined levels of mRNA and protein expression of MHC class I 
proteins, as well as several MHC class I antigen processing and presentation 
chaperones in mESCs and PSC (Lampton et al., 2008). They found that H-2K, Qa-2, 
TAP1, TAP2 and tapasin mRNAs were all expressed at low levels in undifferentiated 
and differentiated ESCs which were significantly upregulated in response to IFNγ 
treatment after 14 days of differentiation. Likewise, expression of H-2Kb and H-2Kk 
proteins were upregulated to measurable levels by IFNγ after differentiation, but Qa-2 
protein expression remained low or absent. They also found that MHC class I, TAP1, 




T-cells, suggesting transcriptional regulation of these genes in ESCs (Lampton et al., 
2008). 
It was reported that MHC class I molecules were generally up-regulated when mESC 
differentiate into teratomas in vivo (Nussbaum et al., 2007). Another study suggested 
that mESCs only transiently, between day 4 and day 6 of differentiation, slightly up-
regulate MHC class I protein expression (Abdullah et al., 2007). Also regarding the 
susceptibility of mESCs to the cytotoxic activity of natural killer (NK) cells several groups 
were able to show that mESCs are efficiently killed. This was most likely due to low 
MHC class I molecule expression, which serve as ligand for inhibitory NK cell receptors, 
combined with expression of ligands for activating NK cell receptors (Dressel et al., 
2010; Dressel et al., 2008; Frenzel et al., 2009). In summary, the findings published so 
far suggest that ESCs are probably more immunogenic than initially proposed in many 
early studies, in which a general immune privilege of ESCs was suggested (Bonde and 
Zavazava, 2006; Koch et al., 2008; Li et al., 2004; Magliocca et al., 2006). 
Allogeneic immune response was detected in mice after implantation of labeled 
embryonic stem cells in ischemic myocardium (Kofidis et al., 2005). It was also found 
that mESC transplanted into injured myocardium provoke infiltration of T-cells, B cells 
and macrophages. The transplanted cells and their progeny disappear over a period of 
weeks, most likely because of this response (Swijnenburg et al., 2005). In contrast to 
this, Fandrich et al. showed that allogeneic rat ESC-like cells injected into the portal vein 
induce a state of tolerance that allows survival of cardiac allografts of the same major 
histocompatibility complex (MHC) types as the ESC (Fandrich et al., 2002). 
Transplantation of differentiated ESC in an animal model could enhance MHC-I levels 
and the myocardium could be particularly inductive for an immune response (Drukker 
and Benvenisty, 2004). After myocardial injury, inflammation occurs which leads to 
recruitment of active immune cells (van Laake et al., 2006). It has been demonstrated 
that hESC derived cardiomyocytes can survive and mature after intramyocardial 
injection in immunodeficient mice up to 12 weeks (van Laake et al., 2007). In one of the 




immune rejections in rats (Naito et al., 2004). In contrast transplantation of PSC into 
ischemic myocardium of immune competent animals significantly enhanced 
neovascularization and improved heart function (Liu et al., 2013a). Taken together, 
most of the in vivo experiments with stem cell-derived cardiomyocyte implantations 
were done under immunosuppression or in immune deficient animal models. 
1.7 Interferon gamma and regulation of major histocompatibility complex  
Interferons (IFNs) are proteins released by host cells in response to the presence of 
pathogens or tumor cells. They are typically divided into type I (alpha and beta) and 
type II (gamma) classes. Besides antiviral function, IFNs have broader range of anti-
proliferation and pro-inflammatory activities (Schroder et al., 2004). IFNγ exposure to 
cells can up regulate MHC class I expression on their cell surface and enhance CTLs 
recognition (Rosa and Fellous, 1988). In this way, CTLs kill bacteria and virus infected 
cells via CTL epitope/MHC class I complexes on the surface of target cells (Boehm et 
al., 1997). The components of MHC class I antigen processing machinery are 
upregulated by IFNγ through the JAK/STAT signal transduction pathway (Kohlhuber et 
al., 1997; Wu et al., 1997) (Figure 4). IFNγ performs its biological functions through 
binding to IFNγ-receptor (IFNGR). IFNGR is present on all nucleated cells. 
Initially, it was understood that CD4+ T helper cell type 1 (Th1) lymphocytes, CD8+ 
cytotoxic lymphocytes and NK cells exclusively produce IFNγ (Bach et al., 1997; Young, 
1996). However, now it is known that other cells, such as B cells, natural killer T-cells 
(NKT) and professional antigen-presenting cells (APCs) secrete IFNγ (Carnaud et al., 
1999). IFNγ production by professional APCs (monocyte/macrophage, dendritic cells 
(DCs)) acting locally may be important in cell self-activation and activation of nearby 
cells (Frucht et al., 2001). IFNγ secretion by NK cells and possibly professional APCs is 
likely to be important in early host defense against infection, whereas T-lymphocytes 




       
Figure 4: Interferon-gamma signal transduction pathway. Ligand (IFNγ) binding causes a 
conformational change IFNGR, such that the inactive JAK kinases are activated by phosphorylations. The 
activated JAK phosphorylates STAT1. STAT1 homodimers move to the nucleus and bind to promoter 
IFNγ activation site (GAS) elements to initiate/suppress transcription of IFNγ regulated genes. IRF-1 is 
also able to promote transcription of STAT1 through an unusual ISRE site (IRF-E/GAS/IRF-E). ICAM-1, 
Intercellular adhesion molecule-1; MIG, monokine induced by IFNγ; iNOS, inducible nitric oxide synthase; 
IRF, Interferon response factor; ISRE, Interferon stimulated response element. Figure adapted from 
Schroder et al. (2004). 
1.8 Immune regulatory properties of pluripotent stem cells 
In addition to the proposed immune privilege of ESCs due to undetectable MHC class I 
expression, further mechanisms of ESCs to evade immune responses were reported. 
Such mechanisms appear evolutionary plausible for ESCs since these cells, derived 
from the early blastocyst, need immune escape mechanisms to avoid the maternal 
immune response (Trowsdale and Betz, 2006). Abdullah et al. reported that murine 




(Abdullah et al., 2007). This protein is an endogenous inhibitor of granzyme B, the 
serine protease that enables NK cells and CTLs to lyse target cells via the granule 
exocytosis pathway (Medema et al., 2001). Another known protective protein against 
cellular cytotoxicity is cathepsin B. Cathepsin B is a protease that inactivates the pore-
forming activity of perforin, thereby inhibiting the transport of granzyme B into target 
cells. It was shown that CTLs protect themselves against perforin of their own cytotoxic 
granules by expression of cathepsin B (Balaji et al., 2002). 
Furthermore, it was reported that expression of Fas ligand (FasL) on murine ESCs play 
a crucial role for their immune escape (Bonde and Zavazava, 2006). FasL is a 
transmembrane protein on cytotoxic cells that induces apoptosis in Fas receptor 
expressing cells. In addition to the granzyme B pathway, the expression of FasL is a 
mechanism of CTLs to induce apoptosis in target cells (Nagata, 1996). Cells of immune 
privileged areas such as testis or cornea express FasL, thereby avoiding the cytotoxic 
activity of infiltrating CTLs by a counter attack (Ferguson and Griffith, 1997; Griffith and 
Ferguson, 1997). Accordingly, Bonde et al. reported that 75 % of pre-activated T-cells 
became apoptotic following exposure to murine ESCs and apoptosis was inhibited by 
addition of a FasL neutralizing antibody in a concentration dependent manner (Bonde 
and Zavazava, 2006). However, in other studies no FasL expression on several murine 
ESCs was detected (Brunlid et al., 2007; Frenzel et al., 2009). In addition, no FasL 
expression was detected on human ESCs (Drukker et al., 2006; Grinnemo et al., 2006). 
It was also reported that ESCs evade the immune response by secretion of TGFβ. It is 
well established that TGFβ, released by regulatory T-cells, inhibits the activation of 
naive T-cells. The release of TGFβ by mESCs was demonstrated using ELISA and 
ESC-conditioned medium was able to suppress proliferation of CD4 positive T-cells. 
Proliferation was largely restored after addition of a TGFβ sRII/Fc fusion protein or 
addition of a TGFβ neutralizing antibody (Koch et al., 2008). Indoleamine 2,3-
dioxygenase (IDO), a tryptophan-catabolizing enzyme, suppresses immune reactions 
which is mainly observed in mesenchymal stem cells (MSC). T-cell proliferation is 
inhibited by tryptophan depletion from the cellular microenvironment and further studies 




activation of caspase-8 (Fallarino et al., 2002; Munn and Mellor, 2007; Munn et al., 
1999) 
1.9 Major histocompatibility complex homozygosity 
The issue of immune mediated rejection of an allotransplant remains a major challenge. 
Immunogenicity of a stem cell derivative depends on the expression of the highly 
polymorphic MHC genes. This polymorphism is further increased by genetic 
heterozygosity. The risk of transplant rejection is proportional to the degree of cell-
surface antigen differences between the donor cells and the recipient. In an autologous 
transplant, donor tissue is identical to the recipient. However, autologous transplants 
are not usually practical because of site availability and morbidity. Donor tissues are 
typically screened for cell-surface antigens in order to determine the degree of MHC 
compatibility with the recipient. Matching donor and recipient tissue for HLA antigens 
reduces the chance of a cytotoxic T-cell response in the recipient and thus greatly 
increases the likelihood of transplant survival. In heart transplantation with limited donor 
organ availability only ABO matching is performed (Sjogren et al., 2010). 
 A transplant can be much less immunogenic when its two MHC haplotypes are 
identical resulting in a much higher probability for tissue matching. Grafts derived from 
such homozygous stem cells, presenting as few as three or four antigens, would match 
a much wider range of hosts than a heterozygous graft (Lin et al., 2003). Because some 
HLA haplotypes have a higher distribution in the population, the use of homozygous 
stem cells holds the possibility of creating a bank of stem cells covering most 
phenotypes in the general population (Nakajima et al., 2007).  
Normal ESC derived from fertilized embryos are genetically divergent from any patient 
requiring tissue transplantation (Drukker, 2004). It was estimated that a stem cell bank 
containing 10 stem cell lines from selected homozygous HLA-typed volunteers could 
match 93% of the UK population with a minimal requirement for immune suppression 
(Taylor et al., 2011). Similarly as few as 50 such homozygous lines could potentially 




obtaining homozygous iPSC or ESC on a more global scale are extremely rare or nearly 
impossible. There are several ways to develop MHC homozygous grafts including the 
knockout of one MHC haplotype in a heterozygous stem cell line or the fertilization of an 
oocyte with a sperm that has an MHC identical to the oocyte or generating iPS from 
MHC homozygous donors.  
Even though iPSC seems to provide a perfect match for autologous condition, many 
reports have shown that iPSC derivatives are immunogenic either because of 
reprogramming factors or reprogramming induced DNA damage (Araki et al., 2013; Cao 
et al., 2013; Kruse et al., 2015; Zhao et al., 2011). Because of these limitations with 
HLA homozygosity from hESC and hiPSC as mentioned above one possible alternative 
is to generate HLA homozygous cell lines is by parthenogenesis. PSCs are by nature 
largely haploidentical (75% of the cell lines appear haploidentical for HLA), with only 
crossing over events during meiosis I causing some heteroyogosity (Revazova et al., 
2008)  
1.10 Major histocompatibility complex-haploidentical parthenogenetic stem cells 
The term parthenogenesis is derived from the greek word for “virgin birth”. It is a form of 
reproduction in which an unfertilized egg can develop into a blastocyst and in some 
non-mammalian species even fertile offspring. Several insect species including aphids, 
bees and ants, but also lower vertebrates such as some fish and chicken under 
developmental pressure can reproduce by parthenogenesis (Sarvella, 1973). Recently 
parthenogenesis has received considerable attention as a tool for the production of 
largely haploidentical diploid plutipotent stem cells (Didie et al., 2013; Doulatov and 
Daley, 2013). The possibility of deriving stem cells from parthenogenetic blastocysts  
without destruction of an embryo makes parthenotes also ethically widely acceptable 
and because of their typical haploidentical HLA gene loci an advantage as to HLA 
matching in an allograft setting (Wininger, 2004). A potential concern of haploidentity is 




The phenomenon of parthenogenesis was discovered in the 18th century by Charles 
Bonnet. The molecular events that lead to oocyte activation have been studied in detail 
in invertebrates, amphibians and mice. Mouse parthenotes are capable of developing 
beyond the post implantation stage (day 10 of gestation) in vivo (Kaufman et al., 1977; 
Kono et al., 2004; Surani et al., 1984); porcine parthenotes have developed up to post-
activation day 29 (limb bud stage, past the early heart beating stage); rabbit parthenotes 
until day 10–11 (Ozil, 1990); primates (Callithrix jacchus) have only been shown to 
implant (Marshall et al., 1998); in humans, parthenogenesis can occur and lead to 
ovarian teratomas (Oliveira et al., 2004), but not to full embryonic development. The 
reason for the arrested development in parthenotes is believed to be due to genomic 
imprinting. In normal zygotes maternal and paternal haploid genomes are epigenetically 
distinct and both sets are required for successful development of the organism (Sasaki 
et al., 1992; Surani et al., 1990). Since all genetic material in parthenotes is of maternal 
origin, there is no paternal imprinting component and this prevents proper development 
of extra embryonic tissues whose expression is regulated by the male genome (Surani 
and Barton, 1983). 
There is no confirmed example of unassisted mammalian parthenogenetic reproduction, 
but mammalian oocytes can be artificially activated to undergo parthenogenesis in vitro 
by a two-step protocol involving the treatment with a chemical agent (ionomycin, 
ethanol, or inositol 1,4,5-triphosphate) to elevate Ca2+ levels transiently, followed by 
application of an inhibitor of protein synthesis (cycloheximide) or protein 
phosphorylation (6-dimethylaminopurine(DMAP)) (Hipp and Atala, 2004). Success rates 
and viability appear to be species dependent.  
Mouse oocytes can be activated to undergo parthenogenesis by exposure to Ca2+ and 
Mg2+ free medium; medium containing hyaluronidase; exposure to ethanol, Ca2+ 
ionophores, or chelators; inhibitors of protein synthesis and electrical stimulation (Surani 
et al., 1984). Pronuclear formation and cleavage occurs following incubation with 
calcium ionophore and puromycin or DMAP (Nakagawa et al., 2001). Broad 
differentiation capability of primate (Macaca fascicularis) pluripotent stem cells derived 




characterized dopaminergic neurons (Cibelli et al., 2002) and hepatocytes (Espejel et 
al., 2014) was established. Parthenogenetic stem cells (PSCs) showed self-renewal 
capacity and indefinite proliferation in vitro, but with impaired embryonic and extra 
embryonic development as a consequence of altered genomic imprinting in vivo (Allen 
et al., 1994; Nagy et al., 1989; Spindle et al., 1996). Specification to ectodermal 
differentiation is not effected in vitro (Vrana et al., 2003) and in vivo (Sturm et al., 1994), 
while endodermal and mesodermal cell lineage specifications are compromised 
developmentally in parthenotes (Allen, Barton et al. 1994). The first human PSC line 
was unintentionally created in a failed nuclear transfer experiment (Mai et al., 2007). 
Revazova et.al created intentionally, six pluripotent HLA heterozygous human PSC 
lines by chemical activation of unfertilized oocytes harvested directly from explanted 
ovaries of patients undergoing super ovulation treatment (Revazova et al., 2007). Since 
then several human parthenogenetic stem cell lines have been reported (de Fried et al., 
2008; Hao et al., 2009; Mai et al., 2007).  
Using various activation protocols, it is possible to create PSCs with different HLA 
status. Parthenogenetic activation of immature oocytes (MI) and inhibiting the extrusion 
of first polar body prevents segregation of homologous chromosome pairs (Daughtry 
and Mitalipov, 2014). This result in the generation of haploid PSC, however the 
acquisition of MI oocytes is not trivial. Parthenogentic activation of meiosis II (MII) 
oocytes with a combination of the activating agent’s ionomycin and 6-
dimethylaminopurine (6-DMAP) blocks the extrusion of the second polar body; 
therefore, activated oocytes retain all of their genetic material (Figure 5). The HLA 
genotypes of hPSCs derived from these oocytes can be heterozygous or homozygous 
due to crossing over events and thus can be genetically HLA-matched to the donors 




                         
Figure 5: Embryonic and parthenogenetic meiosis. A. During normal fertilization the maternal or 
paternal chromosomes segregate into the first polar body (1
st
 PB) in meiosis I (MI). In meiosis II (MII) a 
further reduction of the chromosomal DNA occurs by the separation of sister chromatids and the 
extrusion of one set of chromatids as the second polar body (2
nd
 PB). Fusion of two haploid gametes 
(oocyte and sperm) results in a diploid zygote B. In heterozygous parthenogenesis, meiosis II (MII) 
arrested oocytes are activated artificially by blocking extrusion of the second polar body. Diploidy is 
maintained and the resulting blastocysts yield hetrozygous diploid parthenote. C. In homozygous 
parthenogenesis  autodiploidization of haploid genome occurs leading to the formation of homozygous 
diploid parthnotes. D. In haploid parthenogenesis haploid genome is maintained through following mitotic 
divisions resulting in the formation of haploid parthnote. PI: prophase I. Figure adapted from Daughtry 
and Mitalipov (2014). 







2 Aims of the thesis 
The main aim of the thesis was to study the immunological properties of MHC-
homozygous PSC-derived cardiomyocytes in vitro and in vivo, with the long-term 
objective to apply engineered heart muscle derived from PSC-derived cardiomyocytes 
in human heart repair.  
The following specific aims were addressed: 
1) Set-up of a bioreactor differentiation protocol for cardiomyocytes derivation from 
PSC. 
2) Generation of engineered heart muscle (EHM) from PSC-derived 
cardiomyocytes. 
3) Characterization of the immunological properties of PSC-derivatives and PSC- 
EHM in vitro and in vivo. 
4) Characterization of immunogenicity of MHC-homozygous PSC-derived non-
myocytes and cardiomyocytes in vivo. 
 
Figure 6: Schematic representation of the project. 
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3 Materials and methods 
3.1 Molecular biology methods 
3.1.1 Transformation of competent cells 
50 µl of competent E.coli cells (DH5α) were thawed on ice and incubated with 1 µl of 
plasmid (10-100 ng) and kept on ice for 30 min. The transformation reaction mixture 
was then subjected to heat shock at 42°C for 1 min and then immediately kept on ice for 
2-3 min. In order to accelerate the bacterial growth, 250 µl of SOC medium (Invitrogen) 
was added to the mixture and incubated at 37°C, with shaking for 1hr. The SOC 
medium with bacteria (50 -100 µl) was then plated on LB agar plates containing 
ampicillin (100µg/ml) and incubated at  37°C for less than 16 hrs. 
3.1.2 Plasmid DNA preparation 
Colonies were picked from the LB-agar plates and cultured in 50 ml polypropylene 
tubes (Falcon) containing 5 ml of LB medium (Appendix) and 100 μg/ml ampicillin. The 
liquid culture was incubated at 37°C with shaking at 450 rpm for 8 to 12 hrs till an optical 
density (OD) of 0.6 was reached. Plasmid DNA was extracted and purified from DH5α 
cells as follows:  2 ml of the liquid culture was transferred to 2 ml reaction tubes 
(Eppendorf). Cells were pelleted by centrifugation at 14,000 × g for 30 seconds. The 
supernatant was decanted and the pellet was resuspended in 250 μl buffer P1 
(QIAGEN, Cat#19051) by vortexing. 250 μl of buffer P2 (QIAGEN, Cat#19052) was 
added to the homogenous cell suspension to initiate cell lysis. The tubes were mixed 
well by gentle inversion for several times (without vortexing) and allowed to stand at 
room temperature for 5 minutes (or until the cell suspensions were clear). Lysis reaction 
was neutralized by the addition of 300 μl buffer P3 (QIAGEN, Cat#19053) followed by 
gentle inversion of the tubes. The tubes were kept on ice for 5 minutes and centrifuged 
at maximum speed (20,000 x g) for 10 minutes. Supernatants containing plasmid DNA 
were then transferred to 1.5 ml tubes. 600 μl of isopropanol was added to each tube, 
mixed vigorously and kept at room temperature for 2 minutes to precipitate the plasmid 
DNA. The plasmid DNA was pelleted by centrifugation at maximum speed (20,000 x g) 
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and 4°C for 20 minutes and supernatants were carefully aspirated. 400 μl of 70% 
ethanol was added to each tube followed by gentle inversion to wash the DNA pellets. 
The DNA was pelleted by centrifugation at maximum speed (20,000 x g) and 4°C for 5 
minutes and the supernatants were carefully removed. 
3.1.3 Restriction digestion of DNA 
The restriction analysis was performed with 1 μg DNA in a total volume of 10 μl. The 
DNA sample was digested with restriction enzymes (AflII/HindIII) in the prescribed 
buffer (NEB buffers) at the recommended temperature for 1-2 hrs. At the end of 
incubation, the single and/or double digested DNA samples and undigested controls 
were analyzed by agarose gel electrophoresis (100 ng/lane) and purified if necessary.  
Reaction Mixture: 
DNA                                             1 µl  
NEB buffer                                   1 µl  
BSA                                             1 µl  
AflII enzyme (20,000 U/ml)          0.3 µl 
HindIII enzyme (20,000 U/ml)      0.3 µl  
Sterile H2O                                   6.4 µl  
3.1.4 Polymerase chain reaction 
In order to amplify the genomic DNA or single stranded cDNA, polymerase chain 
reaction (PCR) was performed. For PCR amplification, Takara Ex Taq® DNA 
polymerase (Clonetech) was used. All amplifications were performed using a PCR 
cycler (Veriti® 96-well Thermal cycler; Applied Biosystems) under optimized conditions 
for each target sequence. PCR reactions were performed in sterile 0.2 ml thin wall tubes 
as described below. 
Sequences encoding for the pluripotency markers Oct3/4, Nanog, Sox-2 and Rex-1 as 
well as GAPDH as a house keeping gene were amplified. Primer sequences are given 
in the appendix 2.1 
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4x Reaction-Master Mix: 
10x ExTaq Buffer                          5 µl 
dNTP mix (2.5 mmol/L each)        4 µl 
ExTaq polymerase (5 U/µl)           0.25 µl  
Forward Primer (10 µmol/L)          1 µl        
Reverse Primer (10 µmol/L)          1 µl 
dH2O (36.75 µl) added up to 48 µl. 
PCR conditions 
1. Denaturation   1 min        95°C 
2. Denaturation   15 sec      95°C 
3. Annealing        15 sec      60°C 
4. Elongation       30 sec      72°C 
5. Repeat step 2- 4 for 29-35 cycles 
7. Hold at 4°C until further use 
3.1.5 DNA electrophoresis in agarose gels 
To analyze the PCR products, samples were electrophoretically separated according to 
their molecular size in 2% agarose gels. The agarose was boiled in a microwave for 2-3 
min in 1x TAE buffer and after cooling to (~ 60°C) 2-3 μl of ethidium bromide solution 
(10 mg/ml) per 100 ml gel was added and poured in a gel casting plate. The amount of 
DNA loaded was as follows on a gel: 10 μl of PCR reaction /lane, for plasmid after 
purification 100 ng /lane, for the restriction digest 100 ng /lane. Migration of the DNA in 
the gel can be judged by visually monitoring the migration of the tracking dyes, that is 
bromophenol blue and xylene cyanol present in the DNA loading buffer. After adequate 
migration, DNA fragments were visualized on an ultraviolet transilluminator (due to the 
intercalation of the fluorescent dye ethidium bromide into the double strand of DNA, 
DNA becomes fluorescent) and photographed by a camera attached to a gel 
documentation system (GelDocTM XR imaging system, Biorad). In order to define the 
size of the DNA fragments, DNA size marker was also loaded on the gel. 
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3.1.6 Isolation of DNA fragments from agarose gels 
The linearized DNA fragments were eluted from the agarose gel using QIAquick gel 
extraction kit (QIAGEN) based on the manufacturer´s protocol. After gel electrophoresis, 
the appropriate DNA fragment with proper size was carefully excised from the agarose 
gel with a clean, sharp blade. The excised gel was weighed in a 2 ml reaction tube 
(Eppendorf) and 300 μl of Buffer QG was added per 100 mg of gel. The tubes were 
incubated at 50°C for 10 minutes. After the gel slice was completely dissolved, 100 μl of 
isopropanol was added to the tube and mixed well by vortexing. The mixture was then 
transferred to a QIAquick spin column with a 2 ml collection tube and spun at 13,000 x g 
for 1 minute. The flow-through was discarded. The column was washed with 0.5 ml 
Buffer QG and centrifuged at 13,000 x g for 1 minute. The flow-through was discarded 
and the column was washed with 0.75 ml PE Buffer. After centrifugation at 13,000 x g 
for 1 minute, the flow-through was discarded, and the centrifugation was repeated once 
to remove residual wash buffer. The column was placed into a clean 1.5 ml tube and 50 
μl Buffer EB was added to the center of the column. The tube was allowed to stand at 
room temperature for up to 4 min and the DNA was eluted from the column by 
centrifugation at 13,000 x g for 1 minute. The concentration of DNA was quantified 
using a spectrophotometer (Nanodrop, ND-1000, Thermo Scientific). 
3.1.7 Plasmid DNA preparation  
After the confirmation of purified plasmid DNAs, a large scale preparation (maxi prep) 
was carried out using the NucleoBond Xtra Maxi kit (Macherey-Nagel). 1 ml of starter 
bacterial culture was mixed with 250 ml LB medium (Appendix) containing 100 μg/ml 
ampicillin in a 1 L conical flask. The mixture was incubated on a shaker at 37°C 
overnight. The following steps were performed based on manufacturer´s protocol for 
low-copy plasmid purification. 250 ml of bacterial liquid culture was transferred into an 
ultracentrifuge tube and spun at 6,000 x g for 15 minutes at 4°C. After discarding the 
supernatant, the cell pellet was completely resuspended in 24 ml of Buffer RES+RNase 
A by pipetting the cells up and down. 24 ml of Buffer LYS was added to the suspension 
and mixed thoroughly by gentle inversion until a homogeneous cell lysate was obtained. 
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The cell lysate was then incubated at room temperature for 5 minutes. During the 
incubation period, a NucleoBond® Xtra Column together with the inserted column filter 
was equilibrated with 25 ml of Buffer EQU. 24 ml of Buffer NEU was added to the 
suspension and the cell lysate was mixed by gentle inversion. The cell lysate was then 
loaded into the equilibrated NucleoBond® Xtra Column Filter. The column filter 
containing cell lysate was washed with 15 ml of Buffer EQU. The column filter was 
discarded and 25 ml of Buffer WASH was applied to the center of NucleoBond® Xtra 
Column. The plasmid DNA was eluted by the addition of 15 ml of Buffer ELU and the 
eluate was collected in a 50 ml centrifuge tube. The eluted plasmid DNA was then 
precipitated by adding 10.5 ml of isopropanol at room temperature and mixed 
thoroughly using a vortex. The tube was centrifuged at 15,000 x g for 30 minutes at 4°C. 
After discarding the supernatant, the DNA pellet was washed with 70% ethanol at room 
temperature and centrifuged again at 15,000 x g for 30 minutes at 4°C. The DNA pellet 
was allowed to air-dry at room temperature and reconstituted with appropriate volume of 
buffer TE. The resulting purified plasmid DNA was quantified by a spectrophotometer 
(Nanodrop, ND-1000, Thermo Scientific). 
3.1.8 PCR for microsatellite markers 
In order to analyze microsatellite marker D17Mit178 located on the chromosome 17 the 
double stranded genomic DNA from different non transgenic PSC-lines was isolated. 
PCR was performed to amplify the D17Mit178 locus (refer to appendix 2.1 for primer 
sequence information). For PCR amplification, Takara Ex Taq® DNA polymerase 
(Clonetech) was used. All amplifications were performed using PCR cycler (Veriti®96 
well thermocycler, Applied Biosystems) under optimized conditions for each target 









1. Denaturation     15 sec 95°C 
2. Annealing          15 sec 60-56°C 
3. Elongation          20 sec 72°C 
Repeat steps 1, 2 and 3 for 20 cylces 
4. Denaturation      15 sec 95°C 
5. Annealing           15 sec 56°C 
6. Elongation          15 sec  72°C 
Repeat steps 4 for 15 cycles 
7. Hold at 4 °C 
After amplification the products were separated by electrophoresis and visualized after 
incubation with ethidium bromide. 
3.2 Cell culture techniques 
3.2.1 Preparation of murine embryonic fibroblasts feeder cultures 
PSCs are usually grown on a layer of mitotically inactivated primary MEFs in the 
presence of leukemia inhibitory factor (LIF) to promote growth and prevent 
differentiation. Mouse embryos (NMRI strain) were harvested at day 13 post coitum 
(p.c., assuming day one is the first day the plug is observed) following timed 
pregnancies after euthanasia of the pregnant mouse by cervical dislocation. The heads 
and internal organs (liver, heart) were dissected prior to enzymatic dissociation in 0.25% 
trypsin to produce single cell suspensions. MEFs were expanded in MEF medium 
(Appendix 2) on 15 cm culture plates. After enzymatic dispersion (0.25% trypsin) MEFs 
were suspended in cryopreservation medium (1 ml), frozen and stored in liquid nitrogen. 
MEFs were mitotically inactivated prior to use as a feeder layer either by γ-irradiation 
(30 Gy) or mitomycin C treatment (50 µg/ml). We routinely used irradiated MEFs for 
PSC- maintenance. 
A frozen vial of P0 MEFs was thawed and plated in a 15 cm tissue culture plate with 
MEF medium. The cells were allowed to grow until confluent (3 to 5 days). Medium was 
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changed after the first day and every other day thereafter. The cells were then 
passaged by trypsinization and resuspended in 10 ml MEF medium followed by plating 
at a 1:10 dilution. Medium was added to a final volume of 25 ml in 15 cm plate. The 
cells were allowed to grow until confluent (3 to 5 days) and passage at a 1:5 to 1:10 
dilution, using twenty-five to fifty 150 cm cell culture plates. Medium from confluent 
plates was removed and the cells were rinsed with 15 ml Ca2+ and Mg2+ free PBS and 
overlayed with 0.25% trypsin. MEFs from ten to fifteen 15 cm cell culture plates were 
typically processed in parallel. The pellet was resuspended in 10 ml MEF medium and 
transferred in suspension to a 50 ml falcon tube at a concentration of 2 million cells per 
ml. The cells were then exposed 2 times to 30Gy of γ-radiation (Biobeam 8000) for 15 
min each. The number of cells was counted and either used freshly for PSC-culture by 
plating (1 x 106 cell/10 cm dish) or frozen (8 x 106 cells/ vial) for later use. 
3.2.2 Freezing and thawing of cells 
PSCs and MEFs were trypsinized, washed, centrifuged and resuspended in medium. 
The cell concentration was adjusted to 1-2 x 106 cells per ml and 0.5 ml of this 
suspension was mixed with 0.5 ml of cell freezing medium (Appendix 2) containing 80% 
FBS and 20% DMSO. Aliquots of cells (1-2 x 106 cells/1 ml) were frozen at -80°C 
overnight and for long-term storage transferred to liquid nitrogen. For thawing, frozen 
cells were quickly transferred from liquid nitrogen into a 37°C water bath, thawed, 
washed with 10 ml of pre-warmed medium and seeded on a dish coated with 0.1% 
gelatin or seeded with irradiated MEFs (see above) depending on the requirements of 
the experiment. 
3.2.3 Neomycin selectable parthenogenetic stem cell lines 
Approximately 5 x 106 PSC were resuspended in 800 μl PBS. 20 μg of a linearized 
plasmid encoding for a neomycin-resistance (NeoR) under control of a cardiomyocytes-
specific 5.5 kb αMHC promoter fragment and a hygromycin resistance (Hygro R) under 
the control of ubiquitously active phosphoglycerate kinase (PGK) promoter (kindly 
provided by Prof. Loren J. Field, Indianapolis, USA) was diluted in 100 μl of PBS and 
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mixed with the cell suspension. The mixture was transferred into a GenePulser cuvette 
(0.4 cm electrode, gap 50). The cell and plasmid mix was incubated on ice for 20 
minutes. Electroporation was then performed using GenePulser Electroporator (BioRad) 
at 300 V and 1200 μF, pulse 2 ms. Immediately after electroporation the cell suspension 
was transferred to a 10 cm dish containing 10 ml of stem cell medium with LIF and 
layered with irradiated MEFs prepared one day earlier. Selection of resistant colonies 
was started 48 hrs later by addition of hygromycin at a concentration of 200 μg/ml. 
Approximately 10 days later resistant colonies were obtained. 11 colonies were picked 
and sub cultured as separate clones. All clones were expanded and frozen in multiple 
vials. At least four positive clones (by PCR for NeoR gene) were chosen for the initial 
round of screening for cardiac differentiation. Clone-10 was randomly chosen and all the 
data shown in this study is from αMHC-Neo PSC clone 10. 
3.2.4 Characterization of parthenogenetic stem cell clones 
DNA was extracted from cultured cells using DNeasy Blood & Tissue Kit (QIAGEN) 
following the manufacture´s protocol. In brief, 1-2 x 106 cells were collected and pelleted 
at 300 x g for 5 minutes. The cell pellet was resuspended with DPBS and cells were 
lysed with Buffer AL containing proteinase K. After incubating at 56°C for 10 minutes, 
DNA was precipitated by adding 96-100% ethanol and mixing thoroughly. Samples 
were transferred into DNeasy Mini spin columns and spun at 7000 × g for 1 minute to 
allow DNA to bind to the membrane of the columns. The columns were washed with 
Buffer AW1 and AW2 in sequence. Finally, DNA was eluted from the columns by adding 
Buffer AE. PCR reactions were carried out using GeneAmp® PCR System 9700 
(Applied biosystems) and Takara Ex Taq® DNA polymerase (Clonetech). The primer 
sequences for detecting the transgene neoR are listed in appendix 2.1. PCR conditions 
are described below. PCR products were separated by electrophoresis in 1% agarose 
gels as described above 
 
 




dNTP (2.5 mmol/L each)          1.6 µl 
10x buffer                                2 µl 
Forward primer (10 mmol/L)                  0.2 µl 
Reverse primer (10 mmol/L)                  0.2 µl 
Extaq polymerase (5 U/µl)                     0.1 µl 
DNA (500 ng/µl)                                2 µl 
Distilled water                                13.9 µl 
PCR Conditions: 
1. Denaturation   30 sec  94°C      
2. Denaturation   10 sec  98°C     
3. Annealing        30 sec  61°C              
4. Elongation       30 sec  72°C      
5. Repeat steps 1-4 for 35 cycles 
6. Elongation      5 min     72°C      
Hold at 4°C      
3.2.5 Culture of parthenogenetic stem cells 
PSC-colonies were cultured on feeder layer cells (MEFs). At least one day before 
plating the PSC-colonies, 10 cm culture dishes (Nunclon™Δ) were coated with 0.1% 
gelatin and incubated at 37°C in a humidified incubator with 5% CO2 for 10 minutes. 
One million inactive MEFs were plated and cultured with MEF medium. Medium was 
changed after 24 hrs. The MEFs plates were kept at 37°C in a humidified incubator with 
5% CO2 one week before use. PSCs were suspended in stem cell medium (SC 
medium). 1 x 106 cells were plated on the MEFs dishes and cells were evenly 
distributed by swirling the dishes gently. Medium was changed daily. When the cell 
density reached 80% confluence, cells were split into fresh MEFs dishes at 1:3 or 1:6 
ratio. Medium was aspirated and cells were washed with DPBS (without Ca/Mg) once. 3 
ml of Trypsin/EDTA (0.25%; Invitrogen) was added to a 10 cm dish and incubated at 
37°C in a humidified incubator with 5% CO2 for 3 minutes. Trypsin/EDTA was 
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inactivated by adding 5 ml of SC medium (Appendix 2). Single cell suspension was 
obtained by trituration. The single cell suspension was then transferred to a 15 ml tube 
and pelleted at 300xg for 5 minutes. Supernatant was removed and the pellet was 
resuspended with 5 ml fresh ES medium. Cell number was counted by CASY cell 
counter (Model TT, Roche Innovatis AG) and required number of cells (approx.1 million) 
was plated onto 10 cm fresh MEF dishes. 
3.2.6 Assessment of proliferation rate 
5 x 104 undifferentiated PSC were plated on MEF-seeded culture dishes (6 cm2). Cells 
were isolated (triplicates) for every 12 hrs with Trypsin/EDTA (0.25%). The cell number 
was determined using a CASY cell counter (Model TT, Roche Innovatis AG). The 
doubling time was calculated from the linear interval of the resultant growth curve.  
DoublingTime = duration × log (2)/log (Final cell count) −log (Initial cell count) 
3.2.7 Assessment of cardiac differentiation  
To evaluate the efficiency of cardiac differentiation, each PSC clone was differentiated 
in vitro in hanging drop embryoid body (EB) cultures. For this, cell colonies were 
dissociated into single cell suspensions by trypsinization as described before. The 
feeder layer cells (MEFs) were removed by preplating for 30 minutes. After preplating, 
the supernatant was collected in 50 ml tubes and the number of cells was counted using 
a CASY cell counter (Model TT, Roche Innovatis AG). After cell counting, cell 
suspensions were diluted to 500 cells per 20 μl of differentiation medium (Appendix 2). 
20 μl drops were placed on the lids of 15 cm culture dishes using a multichannel pipette 
and carefully inverted to cover the dishes. Each dish contained 15 ml DPBS to prevent 
the drops from drying out. The 15 cm dishes were incubated at 37°C in a humidified 
incubator with 5% CO2. After 3 days, EBs were collected by rinsing the lids with 10 ml 
differentiation medium and transferred to 10 cm petri dishes for suspension culture for 2 
more days. After suspension culture, EBs was plated onto 10 cm cell culture dishes 
coated with 0.1% gelatin for adhesion culture. On day 11 (11 days after the initiation of 
hanging drops), 200 μg/ml of geneticin (G-418, PAA) was added into the differentiation 
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medium to select for cardiomyocytes. The differentiation and selection were terminated 
on day 18. The morphology of the EBs and beating activities were observed daily 
throughout the period of differentiation. The clone with highest beating activity (αMHC- 
Neo PSC clone 10) compared with other clones was chosen for further experiments. 
3.2.8 Differentiation in spinner flask cultures 
To enhance the culture process, spinner flask cultures were implemented. PSCs were 
cultured and passaged as described before. Before initiating differentiation, cells were 
passaged at least two times. PSC colonies were dissociated into single cells by 
trypsinization as described before. After preplating for 30 minutes to reduce the MEF 
content, cell suspensions were collected in 50 ml tubes and cell number was counted. 
10 million cells were transferred to another 50 ml tube and pelleted by centrifugation at 
300 x g and 4°C for 5 minutes. After centrifugation, the supernatant was removed and 
the pellet was resuspended with 25 ml differentiation medium. The cell suspension was 
then transferred into a 125 ml culture vessel (Techne, F7988) containing 25 ml of 
differentiation medium. The stirring speed was set to 60 rpm (day 0). On the next day 
(day 1), 50 ml of differentiation medium was added into the culture vessel. Half of the 
medium was replaced every other day. On day 11, 200 μg/ml of geneticin (G-418, PAA) 
was added to the medium for the selection of cardiomyocytes. After 7 days of selection, 
EBs were harvested and digested into single cardiomyocytes for further experiments. 
 
Figure 7: Schematic overview of PSC differentiation in spinner flasks. A. Stirred suspension culture 
in a spinner flask is depicted below. 
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3.2.9 Assessment of contractility in embryoid bodies 
EBs formed after 3 days of culture in spinner flasks were transferred into gelatin coated 
48 well plates at a concentration of one EB per well. The number of beating EBs was 
counted in each well every alternate day (days 5, 7, 9,11,13,15 and 17). 
3.2.10 Dissociation of embryoid bodies 
EBs were collected from the culture vessel and transferred into two 50 ml polypropylene 
tubes (Falcon). The tubes were placed upright for 5 minutes to allow EBs to sediment. 
The supernatant was aspirated and EBs were washed with 20 ml of DPBS and 
resuspended with 6 ml of collagenase I (Sigma) containing 20 μl/ml DNase I 
(Calbiochem). The tubes were incubated at 37°C for 1 hour in a warm chamber with 
shaking. 20 ml of DPBS (w/o Ca2+/Mg2+) was added and single cells were obtained by 
triturating with a 10 ml pipette few times. The cells were pelleted by centrifugation at 
200 x g for 5 minutes at room temperature. For further digestion, the pellet was 
resuspended with 5 ml 0.25% trypsin-EDTA and incubated at room temperature for 10 
minutes. The trypsin suspension was gently triturated with 5 ml pipette to yield single 
cell suspensions. The enzyme digestion was neutralized with 20 ml differentiation 
medium containing 20 μl/ml DNase and then triturated further using a 10 ml pipette. The 
cells were pelleted by centrifugation at 200 x g for 5 minutes at 4°C. After resuspension 
in 10 ml differentiation medium, the suspension was passed through a 70 µm cell 
strainer to remove cell clumps. Number of cells was then counted by staining with 
trypan blue dye solution on a Neubauer counting chamber.  
3.2.11 Preparation of engineered heart muscle 
Self-made glass culture dishes consisting of 4 ring-shape molds (inner/outer diameter: 4 
/10.6 mm) were used for casting the EHMs (Figure 8A). The volume inside each mold 
was 450 μl. All the pipetting steps were carried out on ice to prevent premature 
polymerization of the EHM reconstitution mixture. 1.5 x 106 cell mixture containing 70% 
of PSC-derived cardiomyocytes and 30% non-cardiomyocytes (inactivated MEFs) were 
mixed and resuspended with appropriate volume of differentiation medium. An equal 
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amount of 2X DMEM was added to collagen type I dissolved in 0.1% acetic acid (rat tail 
collagen). The pH was adjusted to (~7.4) with 0.1 N NaOH. Finally, the proper amount 
of cell suspension was added into the mixture. A standard pipette scheme for 
generating four EHMs is given below. Homogeneity of cell-collagen mixtures was 
achieved by careful trituration with a pre-cooled 2 ml pipette. 450 µl of mixture was cast 
into each mold and incubated at 37°C in a humidified incubator with 5% CO2 for one 
hour. After initial condensation of the collagen, 6 ml of differentiation medium was 
added into each glass culture dish. 
The EHMs were incubated at 37°C in a humidified incubator with 5% CO2 for three 
days. On day 3, EHMs were transferred to static stretchers (Figure 8B) and kept in 
culture for 10 more days. Medium was changed every other day during the entire 
culture time. 
Pipette Scheme for preparation of 4 EHMs 
1. Collagen (0.4 mg/ml)               419 µl 
2. 2X DMEM                                419 µl  
3. NaOH (0.1N)                            82 µl           
4. Cell Suspension                       1180 µl 
Composition of 2X DMEM: 
FCS (PAA-102)                   40% 
10X DMEM                          20% 
P/S (100 units/ 100 µg/ml)   2% 
Adjusted to the final volume with distilled water                   




Figure 8: Preparation of EHM. A. 3 days of culture in casting molds B. EHMs transferred onto a static 
stretcher and cultured for 7 days C. EHM subjected to isometric force measurement in an organ bath. 
3.2.12 Isometric contraction measurements 
On day 10~12, EHMs were suspended between retaining hooks and force transducers 
inside organ baths containing Tyrode´s solution (Appendix 2) (Figure 8C). The 
temperature in the organ baths was maintained at 37°C and the pH was adjusted to 7.4 
with carbogen (95% O2, 5% CO2 gas mixture). After 15 minutes of equilibration, EHMs 
were electrically stimulated at 4 Hz with pulse duration of 5 ms and 200 mA current. 
EHMs were pre-stretched under 1.8 mM [Ca2+] till the force reached a stable maximal 
level (Lmax) according to Frank-Starling mechanism. The solution inside the organ 
baths was replaced with fresh Tyrode´s solution containing 0.2 mmol/L [Ca2+]. 
Contraction forces were initially measured under cumulatively increasing [Ca2+] (0.2-2.8 
mmol/L). Contractile force was recorded at steady state i.e. typically 5 minutes after 
addition of calcium. The maximum and minimum forces were measured by PC-based 
acquisition software (BMON, Engineering firm G. Jaeckel, Hanau). Force of contraction 
(FOC) was calculated by the difference between maximum (peak systolic force) and 
minimum (diastolic) forces. 
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3.2.13 Flow cytometry analysis 
Single cells were prepared as described above by trypsinization. The dissociated cells 
were centrifuged, washed and filtered through a 40 μm cell strainer (BD Pharmingen).  
3.2.13.1 Live cell staining 
Cell count was determined using a CASY cell counter (Model TT, Roche Innovatis AG) 
before suspension in an appropriate volume of staining buffer (PBS supplemented with 
5% FBS) to obtain a cell density of 0.5 x 106 cell/ 50 µl. Cells were then dispensed into 
FACS tubes and stained either with isotype control or antigen-specific antibodies diluted 
in the staining buffer. Cell-surface antigen expression was detected using fluorescently 
conjugated antigen-specific antibodies (direct staining) or labeling the cells with 
unconjugated primary antibody followed by fluorescently-tagged secondary antibody 
(indirect staining) by incubating at 4°C for 30 minutes (Appendix 2.2). The cells were 
washed two times with 1X PBS. Unstained samples were used as a negative control. 
The cell suspension was measured and data was acquired on flow cytometer (BD LSRII 
flow cytometer, FACSDiva software, BD Biosciences). Cells were gated on forward and 
side scatter dot plots. 10,000 events per sample were acquired and the data were 
analyzed with flowing software (free software version 2.5.1). Hoechst (BD biosciences) 
or sytox (life technologies) was used for gating of viable cells. 
3.2.13.2 Fixed cell staining 
Cells were counted and fixed in methanol stabilized 4% formaldehyde (Histofix) for 20 
minutes at room temperature. Supernatant was discarded after centrifugation at 300 x g 
for 5 minutes and washed with 1X PBS once. Cells were then transferred to FACS 
tubes and incubated in blocking buffer (5% FBS, 1%BSA, 0.5% Triton X-100 in PBS) for 
10 minutes on ice. After incubation cells were centrifuged and the supernatant was 
drained by inversion of the tubes. Antibody solutions were prepared by diluting them in 
blocking buffer. Cells were incubated with primary antibody for 45 minutes followed by 
washing with blocking buffer for two times. Secondary antibody solution was then added 
and incubated for 30 minutes at room temperature in dark. The cells were than washed 
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twice with blocking buffer and finally resuspended in 0.5 ml of PBS and proceeded for 
flow cytometry analysis. Cells were gated on forward and side scatter dot plots. 10,000 
events per sample were acquired and the data were analyzed with flowing software 
(version 2.5.1). Hoechst (BD biosciences) or sytox (life technologies) was used for 
gating cell viability.  
3.2.14 Flow cytometry of immunological molecules 
Approximately 5 ml of the EB containing suspensions from spinner flask cultures were 
collected and seeded into a 10 cm bacterial suspension culture dish. EBs was collected 
before initiating the selection for cardiomyocytes. After selection with G-418, cardiac 
bodies were collected from the spinner flask and transferred into 10 cm bacterial 
suspension culture dish. Mouse recombinant interferon gamma (IFNγ; peprotech) was 
added to unselected EBs and cardiac bodies at a concentration of 25 ng/ml and 
incubated at 37°C in a humidified incubator with 5% CO2 for 48 hrs. After 48 hrs these 
embryoid and cardiac bodies were dissociated as mentioned above and stained for the 
expression of MHC-I (H-2Kd) (Biolegend), MHC-II (I-A/I-E) (BDbiosciences),CD1d 
(Biolegend), CD40 (Biolegend), CD80 (Biolegend), CD86 (Biolegend), PD-L1 
(Biolegend), PD-1 (Biolegend).Staining was done according to the protocol mentioned 
above. After staining the cells were analyzed by flow cytometry. 
3.2.15 Isolation of neonatal mouse cardiomyocytes  
Cardiomyocytes from DBA neonatal mice expressing GFP under alpha Myosin Heavy 
Chain (MHC) promoter were isolated by using then neonatal heart dissociation kit 
(mouse and rat, Miltenyi Biotec 130-098-373). Briefly 10-20 neonatal mouse hearts 
were harvested and transferred into a 10 cm dish containing PBS. Using forceps, 
remaining blood was pumped out. The blood vessels and remaining connective tissue 
were cut away from the ventricles. Enzyme mix 1 (enzyme P- 62.5 µl) and (buffer X- 
2,300 µl) was pre-heated for 5 minutes at 37°C. 2,363 µl of enzyme mix 1 was added to 
138 µl of enzyme mix 2 (buffer Y- 25 µl, enzyme A- 12.5 µl and enzyme D- 100 µl). The 
harvested tissue was transferred in to a gentle MACS C tube, 2.5 ml of the enzyme mix 
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was added and the lid of the “C-tube” was tightly closed. The “C-tube” was inverted and 
incubated at 37°C for 15 minutes. The “C-tube” was then attached onto the sleeve of 
the gentle MACS dissociator and gentle MACS program h_tumor_1 was run. This was 
repeated for two times and after termination of the gentle MACS program, the “C-tube” 
was detached and 7.5 ml of differentiation medium was added. Cell suspension was 
resuspended and filtered through a 70 µm cell strainer. The cells were than centrifuged 
at 600xg for 5 minutes and the supernatant was discarded. The cell pellet was 
resuspended in 10 ml of differentiation medium and incubated on a gelatin coated 10 
cm dish for 1 hour at 37°C in a humidified incubator with 5% CO2. After one hour, the 
supernatant was collected and centrifuged at 300 x g for 5 minutes. The pellet was 
resuspended in 5 ml of differentiation medium and the cells were counted in Neubauer 
chamber. The purity of cardiomyocytes was measured by flow cytometry. 
3.2.16 Isolation of cardiomyocytes by the Langendorff method 
For immunostainings of cardiomyocytes from adult mouse heart, cells were isolated 
from DBA mice by retrograde perfusion of the heart through the aorta with enzyme 
(Liberase/Trypsin) solution according to Langendorff. A 21 G cannula connected to a 
peristaltic pump set was used to ensure constant perfusion at 3 ml/min. All perfusion 
solutions (Appendix 2) were pre-warmed to 37°C for optimal digestion.  
The Liberase concentration was adjusted to 0.021-0.042 mg/ml according to the mouse 
heart size and activity of the liberase batch. Prior to heart isolation, mice were 
heparinized (10 mg/kg), anesthetized (isoflurane) and sacrificed by cervical dislocation, 
the heart was removed quickly and mounted via the aorta onto the cannula, fastened (2 
thread loops around the cannula) and perfused. After 3 minutes, the perfusion buffer 
was changed to a digestion buffer and perfused until the buffer was used up. The heart 
was demounted and transferred into the beaker with the 2.5 ml digestion buffer. The 
atria were removed, and the heart was mechanically minced for 30 seconds using small 
scissors. To inhibit the enzymatic digestion, 2.5 ml stopping buffer 1 were added. To 
further dissociate the remaining pieces of tissue by shearing force, the suspension was 
pulled up and down using a 1 ml insulin syringe without a needle for 3 minutes. The 
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suspension was filtered through a 150 µm cell-culture mesh and the cells were 
sedimented for 5 minutes at room temperature. The cell pellet was resuspended in 
stopping buffer 2.  
Calcium concentration was slowly increased to 1 mmol/L by adding 50 µl of 10 mmol/L 
calcium chloride solution twice, 100 µl of 10 mmol/L calcium chloride solution, 30 and 50 
µl of 100 mmol/L calcium chloride solution. The cardiomyocytes were left to equilibrate 
for 4 minutes at each step. Following calcium adaptation, cells were incubated at 37°C 
for 15 minutes to sediment the cardiomyocytes. After removal of most of the 
supernatant, cardiomyocytes were carefully resuspended in the remaining supernatant 
(~ 1 ml), and 50 µl cell suspension was seeded on laminin-coated (10 µg/ml) coverslips. 
Next, cells were left to settle down and adhere to the laminin-coated coverslips for at 
least 45 minutes, before cell culture medium was added. Cells were cultured at 37°C 
and 5 % CO2 for 24 hrs with and without IFNγ (20 ng/ml) followed by a staining for β-2-
microglobulin.  
3.2.17 Immunofluorescence imaging 
Cardiomyocytes seeded on coverslips were fixed with acid free (pH 7), phosphate-
buffered formaldehyde (4%) solution (Histofix, Roth) for 10 minutes at room 
temperature, followed by washing with DPBS. The cells were permeabilized and the 
unspecific binding sites were saturated by incubating with blocking buffer containing 5% 
FBS (Gibco), 1% bovine serum albumin (BSA, Sigma) and 0.5% TritonX-100 
(AppliCehm) in DPBS for 30 minutes at room temperature. The cells were incubated 
with primary antibodies developed to bind α-actinin (Sigma), cardiac-troponin I (abcam), 
β 2-microglobulin (abcam) for 60 minutes at room temperature (Appendix 2.2). 
Subsequently incubation with secondary antibody conjugated with fluorescent dye (anti-
mouse Alexa Fluor® 546, anti-rabbit Alexa Fluor® 488, anti-mouse Alexa Fluor® 633 
Molecular Probe®) was performed for 60 minutes at room temperature. Nuclei were 
counterstained with 4’, 6’-diamidino-2-phenylindole (DAPI; 1 μg/ml, 1:1000, Sigma). 
Samples were washed thoroughly with blocking buffer 3 times for 5 minutes with a final 
wash with only DPBS for 5 minutes. A drop of mounting medium (Fluoromount-G, 
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SoutherBiotech) was put on the slide and the cover slip containing the cells was 
inverted over the medium carefully to prevent the trapping of air pockets within the 
sample. The slides were allowed to dry and then imaged. Fluorescent images were 
acquired using laser scanning confocal microscope (LSM710, Zeiss, Germany). 
3.3 Immunological techniques 
3.3.1 Isolation of mouse splenocytes 
Mice (BL6-J and DBA2J) were sacrificed by cervical dislocation and then dissected 
under sterile conditions. Spleens were collected in a dish containing 1X PBS, a 70 µm 
filter was placed into 50 ml polypropylene tube and rinsed with RPMI medium. The 
spleen was then transferred on the filter. With the help of piston of a 5 ml syringe the 
spleen was pressed against the filter to dissociate the cells and continuously rinsed with 
medium. 
RBC lysis was done by incubating the splenocytes with 1X RBC lysis buffer (Biolegend) 
for 5 min at room temperature. The remaining splenocytes were then washed and 
resuspended in 10% RPMI and counted in a Neubauer chamber. These splenocytes 
were used for the co- culture with PSC-derived cells. 
3.3.2 Immune cell proliferation assay 
The influence of PSC-derived cells on the activation or proliferation of splenocytes and 
T-lymphocytes was analyzed using a co-culture approach. 1 x 105 PSC-derived cells, in 
the form of EBs were transferred into suspension culture 48-well cell culture plates. 
Splenocytes were washed with PBS twice to remove serum. The cells were than 
resuspended at double the desired final concentration in PBS (pre-warmed to room 
temperature).10 µmol/L solution of Cell Proliferation Dye eFluor® 670 (ebioscience) in 
PBS (pre-warmed to room temperature) was prepared. This was mixed with the 2X cell 
suspension at 1:1 ratio and incubated for 10 minutes at 37°C in the dark. The eFluor® 
670 dye (Appendix 2) labeling was stopped by adding 4-5 volumes of cold 10% RPMI 
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and incubated on ice for 5 minutes. The cells were then washed 3 times with 10% 
RPMI.   
1 x 106 eFluor® 670 labeled splenocytes were then added to 1 x 105 PSC-derived cells 
(non-myocytes/cardiomyocytes; NM/CM) and cultured for 4 days with 10% RPMI at 37 
°C and 5% CO2. We used two different conditions: PSC-derivatives co cultured with 
DBA splenocytes (MHC-match for H-2d/d locus) and PSC-derivatives co cultured with 
BL6 splenocytes (H-2b/b, MHC-mismatch). Labeled splenocytes treated with 5 µg/mL 
concanavalin A (Con.A) served as positive control. Unlabelled splenocytes treated with 
Con.A served as negative control. Similarly EHMs made with PSC-CM (H-2d/d) and DBA 
MEF (H-2d/d) were incubated with DBA (H-2d/d) and BL6 (H-2b/b) labeled splenocytes for 
4 days on a shaker with RPMI medium (Appendix 2) at 37°C and 5% CO2. Also EHMs 
made with PSC-CM (H-2d/d) and BL6-MEF (H-2b/b) were treated with DBA (H-2d/d)   and 
BL6 (H-2b/b) splenocytes in the same way. A typical experimental set up is shown in 
Figure 9. 
 
Figure 9: Experimental setup for in vitro proliferation assay. Different conditions were tested in a 48 
well plate. Con.A: concanavalin A, NM: non-myocytes, CM: cardiommyocytes, Spl: splenocytes. 
After 4 days of co-culture splenocytes were collected and filtered through 70 µm cell 
strainer to remove the EBs. The strained splenocytes were than stained with Alexa 488 
 Materials and Methods 
43 
 
labelled CD3 (Biolegend) and the proliferation of CD3 positive splenocytes was 
analyzed using flow cytometry.  
3.3.3 Isolation of T-lymphocytes from spleen 
Splenocytes were isolated from spleen as mentioned above. T-lymphocytes were 
isolated from splenocytes by using the mouse Pan T cell isolation kit II (Miltenyi biotec 
130-095-130). 107 splenocytes were resuspended in 40 µl of buffer(containing PBS, pH 
7.2, 0.5% BSA, and 2 mmol/L EDTA).10 µl of Biotin-Antibody Cocktail (Cocktail of 
biotin-conjugated monoclonal antibodies against CD11b, CD11c, CD19, 
CD45R  [B220], CD49b [DX5], CD105, Anti-MHC class II, and Ter-119) was added to 
107 total cells. The cell suspension was mixed well and incubated for 5 minutes in the 
refrigerator (4°C) followed by the addition of 30 µl of buffer per 107 total cells. Finally 20 
µl of anti-biotin microbeads per 107 total cells was added and mixed well. This cell 
suspension was incubated for 10 minutes at 4°C followed by magnetic separation on LS 
columns mounted on a quadro MACS separator (Miltenyi Biotec). A minimum of 500 µl 
cell suspension was added to LS columns, the flow-through containing unlabeled cells 
was collected, representing the enriched T-cells. The column was washed with 3 ml of 
buffer and the pass through was collected representing the enriched T-cells. The cells 
were counted using a Neubauer chamber. T-cell purity was measured by flow 
cytometry. 
3.3.4 In vitro cytotoxicity assay 
To assess cytotoxic effects of T-cells cardiomyocytes were obtained from the spinner 
flask cultures dissociated as mentioned above, and seeded on gelatin coated 96 well 
plates at a concentration of 105 cells per well. T-lymphocytes were isolated from the 
spleens of BL6-J and DBA2J mice as mentioned above and added to the 
cardiomyocytes at a concentration of 106 cells per well (CM: T-cells ratio, 1:10).The co-
culture was incubated at 37°C and 5% CO2 for 4 hrs and proceeded with the 
measurement of cell lysis by using the cytotox 96® non-radioactive cytotoxixity assay kit 
(promega). 
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Briefly 100 µl of 10% RPMI medium was added to all the wells of a 96 well plate. For 
maximum lysis, 10 µl of lysis solution per 100 µl of medium was added and incubated at 
37°C for 45 minutes.  The plate was than centrifuged at 250 x g for 4 minutes. Then 50 
µl of supernatant from all wells was transferred into a fresh 96-well flat-bottom 
(enzymatic assay) plate followed by the addition of 50 µl of substrate mix to each well of 
the enzymatic assay plate. The plate was then covered with foil or an opaque box to 
protect it from light and incubated for 30 minutes at room temperature. Finally 50 µl of 
stop solution was added to each well and the absorbance was recorded at 490 nm or 
492 nm with the help of 96 well plate reader (Flexstation 3, molecular devices). 
Percent cytotoxicity was measured by using the following formula: 
% Cytotoxicity = Experimental – Effector Spontaneous – Target Spontaneous  x 100  
                                     Target Maximum – Target Spontaneous 
The average absorbance values of the culture medium background were subtracted 
from the average absorbance values of experimental, target spontaneous and effector 
spontaneous. Similarly the average absorbance values of volume correction control 
were subtracted from average absorbance values of target maximum.  
3.4 Animal experiments 
All the animal experiments were performed according to institutional and governmental 
guidelines. Animal studies were approved by the Niedersächsisches Landesamt für 
Verbraucherschutz und Lebensmittelsicherheit (LAVES; G15.1841). 
3.4.1 Cell implantation under the kidney capsule  
PSC-derived EBs and cardiac bodies were implanted under the kidney capsule (right 
kidney) of B6D2F1 mice and BL6-J mice (8-15 weeks age; Figure 10). The implantation 
was performed under isoflurane (3%) anesthesia. A vertical incision was made through 
the skin along the animal’s spine, about 2 cm from the base of the tail to the top curve of 
the spine. The kidney was accessed via a deeper 0.5 cm horizontal incision. With the 
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aid of curved blunt glass pastuer pipette the kidney was pulled out gently and a small 
tear was made in the kidney capsule with the help of sharp needle. EBs and cardiac 
bodies were gently placed under the capsule via a blunt 21G cannula. The tear of the 
kidney capsule was then cauterized and the kidney was carefully relocated 
retroperitoneally. The incision closed with a 6-0 Prolene® (Ethicon) suture followed by 
suturing the skin. Upon completion of the surgery, the animal was placed on a warm 
heating pad, to aid in regaining its body temperature. For analgesia, buprenorphine 
(0.05-0.1 mg/kg) was administered subcutaneously in the right flank. 
The kidneys were harvested from the mice at different time points of days1, 3, 7,14,  
and 28 followed by microscopic (Zeiss, Lumar.V12, SteREO) search for beating cardiac 
bodies and proceeded further for histological analysis. The kidneys were divided into 
two halves; one half was used for H&E staining and the other half for 
immunofluorescence staining of α-actinin and CD3. 
 
Figure 10: Schematic overview of implantation experiments. H-2 homozygous PSCs obtained from 
B6D2F1 mice were used for implantation in MHC-match (B6D2F1) and mismatch (BL6) conditions. 
3.4.2 Histological analysis 
Explanted kidneys from the mice were fixed in 4% formaldehyde (in PBS) overnight at 
4°C. Half of each kidney was paraffin-embedded, and sectioned using Leica RM 2165 
microtome (Leica). For hematoxylin-eosin (H&E) staining, tissue slides were 
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deparaffinized and rehydrated by performing 9 washing steps (2X xylene for 20 
minutes, 100% ethanol, 90% ethanol, 80% ethanol, 65% ethanol, 50% ethanol, 25% 
ethanol, tap water; incubation for 5 minutes each). Kidney sections were stained three 
times with hematoxylin and twice with eosin for 2 minutes each at the Department of 
Pathology, University Medical Center, Goettingen. Thanks to Ines Müller from 
Department of Pharmacology and Toxicology for helping with the H&E staining. The 
slides were imaged with an upright microscope (Zeiss, Imager.M2). 
3.5 Statistics 
GraphPad Prism software (GraphPad Software Inc; San Diego) was used to convert 
data sets into graphs (displayed as mean±SEM) and subjected to Student’s t-test, one-
way, or two-way ANOVA test where appropriate. P<0.05 was considered to be 










4.1 Genetic modification of a parthenogenetic stem cell line 
The aim was to stably integrate an antibody resistance gene (NeoR) transcribed under 
the control of the cardiomyocyte specific α-myosin heavy chain promoter (MYH6 
gene)(Klug et al., 1996) into a previously established PSC-line (Didie et al., 2013).  
4.1.1 Determination of growth rate of non-transgenic parthenogenetic stem cell 
lines 
Several of the previously established PSC-lines (Didie et al., 2013) were screened for 
MHC homozygosity by microsatellite marker analysis; the target sequence was located 
on chromosome 17 and its PCR amplification allowed for a differential analysis of the 
DBA (H-2d/d)-and BL6 (H-2b/b)-mouse H2-locus (D17Mit178; Figure 11A). In order to 
identify whether the established PSC-lines exhibit differences in proliferation rate and 
exclude PSC-lines with low proliferation rate 3 different PSC-lines were randomly 
chosen and compared. These analysis confirmed a similar population doubling time in 
PSCA3 (13±1 hours), PSC30B3 (14±0.1 hours) and PSC32D1 (12±1 hours); (Figure 
11B). Finally, the PSC30B3line was chosen randomly for the generation of stable 







Figure 11: MHC genotyping and assessment of PSC growth.  A. Amplification of microsatellite marker 
D17Mit178 on chromosome 17; DNA from BL6, DBA, and B6D2F1 was used as positive control; DNA 
fragment sizes: 164 bp (DBA-H-2
d/d
); 144bp (BL6- H-2
b/b
). B. Comparison of the proliferation rate in H2 
haploidentical PSC-cell lines PSCA3, PSC30B3, and PSC32D1 (n=3 for each time point and PSC-line). 
4.1.2 Confirmation of transgene identity 
A vector encoding for a neomycin resistance (NeoR) gene under the control of the 
cardiomyocytes specific α-myosin-heavy-chain promoter (MYH6 gene–Figure 12A; 
kindly provided by Loren J. Field, Indianapolis; Klug et al. 1996) was amplified in 
bacterial cultures. Five bacterial colonies were picked and plasmid DNA was isolated. 
Restriction enzyme digestion with AflII (cutting site 5,362bp) and HindIII (cutting site 
8,335bp) confirmed the presence of the αMHC-Neo vector: double digestion with AlfII 







Figure 12: Confirmation αMHC-Neo plasmid identity.  A. Vector map of αMHC-Neo plasmid with 
selected restriction sites and relevant inserts highlighted. B. Restriction digests of αMHC-Neo plasmid 
with AflII and HindIII generated the anticipated 8,004bp and 2,973bp fragments. 
4.1.3 αMHC-Neo parthenogenetic stem cell line 
The αMHC-Neo plasmid was amplified and linearized by digestion with HindIII and XhoI 
(Figure 13A) to remove the ampicillin gene from the vector backbone. The HindIII/XhoI 
fragment (8335bp) was purified and subsequently transfected into the PSC30B3 line 
using electroporation. Following hygromycin selection for 2 weeks (plasmid also 
encodes a ubiquitously expressed hygromycin resistance); DNA was extracted from 11 
cell clones and subjected to PCR for the detection of neomycin resistance (NeoR) gene 






Figure 13: Identification of transgenic PSC clones by PCR. A. Restriction digestion of the αMHC-Neo 
plasmid with HindIII and XhoI. The upper band (8,335bp) was cut out and used for transfection after 
purification. B. clones 1, 2, 3, 6, 8, and 10 were detected as transgenically modified based on the 
amplification of the transgenic NeoR (383bp) sequence. The αMHC-Neo plasmid was run on the gel as 
positive control. 
4.1.4 Morphological and molecular evidence for pluripotency  
After transfection, PSC30B3-MHCNeo clone 10 was further cultured and expanded. The 
colonies represented a compact homogeneous morphology characteristic for murine 
pluripotent stem cell cultures (Figure 14A). Semi-quantitative reverse transcription (RT)-
PCR was performed on RNA extracted from the undifferentiated PSC30B3-MHCNeo 
cultures. All investigated pluripotency markers (Oct3/4, Sox-2, Nanog, and Rex-1) were 





Figure 14: Morphological and molecular evidence for pluripotency. A. Morphology of PSC30B3 
colonies at passage 21. B. Stemness markers/pluripotency genes (Oct3/4: 101bp, Sox-2:131bp, Nanog: 
71bp, Rex-1: 232bp) and GAPDH (171bp- used as housekeeping gene for normalization) was amplified 
as an internal loading control. 
4.1.5 Cardiomyocyte differentiation and purification in spinner flasks 
Differentiation of the B3line was established in spinner flasks for 11 days to form EBs 
followed by selection with G-418 for 7 days to eliminate non-myocytes (NM) and support 
the formation of cardiac bodies. Beating of EBs/cardiac bodies from spinner flask 
cultures was systematically evaluated 3 days after additional plating on gelatin-coated 
48-well plates (plating of one EB/cardiac body/well at the indicated time point; Figure 
15). EBs before selection with G-418 (spinner flask culture day 11; Figure 15A) showed 
a heterogeneous morphology and were larger in size compared to cardiac bodies 
formed after selection with G-418 (spinner flask culture day 18; Figure 15B). First 
beating areas in EBs were noticed from day 5 on with 100% of the EBs beating by 
culture day 11(Figure 15C). After addition of G-418 for the removal of non-myocytes 





Figure 15: Morphology and beating in PSC-derived EBs and cardiac bodies. A. Morphology of 
unselected EBs (day 11 in spinner flask culture). B. Cardiac bodies after G-418 selection (day 18 in 





4.1.6 High cardiomyocyte purity after selection 
The cardiac bodies obtained after G-418 selection for 7 days were dissociated and the 
cells were stained for the expression of α-actinin, cardiac-troponin I and myosin heavy 
chain (MF-20) to analyze the purity of cardiomyocytes by flow cytometry. These 
analysis demonstrated 91±2% actinin positive cells, 91±2% of troponin I positive cells 
and 88±3% MF-20 positive cells (Figure 16). Stirred suspension spinner flask cultures 
with an input quantity of 10 x 106 PSCs resulted in 25±5 x 106 cardiomyocytes (n=12 
spinner flask cultures). Note that cardiomyocyte isolation from EBs/cardiac bodies 
requires careful handling and adaptations of the dissociation protocol according to the 
EB/cardiac body size, structure, age and morphology. 
 
Figure 16: Cardiomyocyte purity after selection in spinner flask cultures. Depicted are isotype 
(IgG1) control data (A and D) and detection of canonical cardiomyocyte expressed proteins such as α-
actinin (B), myosin heavy chain (MF-20; C) and cardiac troponin I (E). F. Bar graph shows a summary of 




4.1.7 Morphological properties of PSC-derived cardiomyocytes 
We analyzed the morphology of PSC-derived cardiomyocytes obtained from spinner 
flask cultures after enzymatic digestion. CMs were cultured on gelatin coated cover slips 
for 2 additional days before immunofluorescence labeling of f-actin, α-actinin, and 
cardiac troponin I. Confocal microscopy confirmed the flow cytometry data on 
cardiomyocyte purity and demonstrated the characteristic morphology of stem cell 
derived cardiomyocytes in monolayer culture with the formation of sarcomeres (Figure 
17). 
 
Figure 17: Morphology of PSC-derived cardiomyocytes. Confocal microscopy of PSC-derived 
cardiomyocytes. Panels indicate the respectively labeled structures. Scale bars: 20 µm. 
4.2 Immunological properties of PSC-derived cells 
After successful generation of transgenic PSC-lines to facilitate purification of PSC-
derived cardiomyocytes, we analyzed the expression levels of immunological molecules 
like MHC antigens, co-stimulatory molecules and immunomodulatory molecules like PD-
L1 in PSC-cardiomyocytes. These molecules play an important role in the antigen 




expression of immunological molecules on PSC-derivatives (non-myocytes) obtained 
after differentiation of PSC. 
4.2.1 PSC-derivatives express immunologically relevant surface markers 
PSC-derived cells before selection with G418 (non-myocytes - NM) and after G418 
selection (cardiomyocytes - CM) were treated with mouse recombinant IFNγ (25 ng/ml) 
for 48 hrs. After treatment with IFNγ the cells were dissociated and analyzed by live cell 
flow cytometry. NM showed the expression of MHC-I (H-2Kd) on 35±15% of all cells and 
no MHC-II (I-A/I-E) expression at unstimulated conditions, which was further 
upregulated to 85±3% and 12±2.3% after IFNγ stimulation. CM did not apparently show 
expression of MHC-I(H-2Kd) and MHC-II(I-A/I-E) under baseline conditions; IFNγ 
treatment resulted in MHC-I and MHC-II(I-A/I-E) expression in 55±8% and 35±8% of the 
CMs respectively (Figure 18A,B,C).  
CD1d is a non-classical MHC molecule generally expressed on antigen presenting cells 
such as dendritic cells, activated monocytes, B lymphocytes and T-cells. It was shown 
by many groups that CD1d was upregulated on cardiomyocytes during inflammatory 
conditions like myocarditis and coxsakievirus B3 (CVB3) infections (Huber et al., 2003). 
Taking this into consideration we analyzed the expression of CD1d before and after 
IFNγ stimulation. CD1d expression was not influenced by inflammatory condition. A 
basal expression of CD1d on 20±15% of all NM and on 40±9% of all CM was observed 
(Figure 18D). No significant upregulation of the co-stimulatory proteins CD40, CD80, 
and CD86 was observed in the absence and presence of IFNγ (Figure 18E). In one out 
of 3 experiments CD80 expression on CM and CD86 expression on NM appeared to be 







             
               
         
Figure 18: Flow cytometry analysis of cell surface markers associated with immune responses.  A 
and B represent individual histograms obtained from NM and CM cultures with and without IFNγ 
exposure; grey histogram represent the isotype controls. C-E Bar graphs summarizing the flow cytometry 
data obtained from NM (blue) and CM (red) cultures with and without IFNγ exposure (25 ng/ml for 48 hrs). 




PD-1/PD-L1 pathway plays an important role in the immune regulation mainly in 
immune escape mechanism of transplanted cells (Riella et al., 2012). PD-1 was not 
expressed on PSC-NM and PSC-CM even after IFNγ stimulation (Figure 19A). In 
contrast PD-L1 expression was up-regulated in both NM to 30±7% and CM to 40±9% 
after IFNγ treatment (Figure 19B). 
  
Figure 19: Flow cytometry analysis of PD-L1 and PD-1 associated with immune escape. A. 
Represents individual histograms obtained from NM and CM cultures with and without IFNγ exposure; 
grey histograms represent the isotype controls. B. Bar graphs summarizing the flow cytometry data 
obtained from NM (blue) and CM (red) cultures with and without IFNγ exposure (25 ng/ml for 48 hrs). 
*p<0.05, (two-tailed, unpaired Student’s t-test, n=3). 
4.2.2 Sustained expression of MHC-I on PSC-derivatives 
IFNγ abundance is increased in the overloaded or inflamed heart, mainly because of 
enhanced homing of T-cells, macrophages and dendritic cells under these conditions 




immunologically relevant surface markers were assessed either in the absence or 
presence of IFNγ. To test whether transient inflammation would result in sustained 
immune activation, indicated by sustained expression of MHC-I (H-2Kd), NM and CM 
were stimulated transiently with IFNγ for 48 hours and thereafter kept in culture for 
additional 4 days with regular medium change every other day without IFNγ. The cells 
were dissociated and analyzed by flow cytometry for MHC-I (H-2Kd) expression. 
Abundance of MHC-I remained high in NM and CM even 4 days after withdrawal of 
IFNγ (Figure 20). This experiment suggested that short episodes of IFNγ stimulation 
may lead to long lasting alterations in PSC-immunogenicity. 
                    
Figure 20: Sustained MHC-I expression after transient IFNγ stimulation. Individual histograms 
obtained from NM and CM cultures with transient and without IFNγ exposure; grey histograms represent 
the isotype controls. (n=1). 
4.3 Functional and immunological properties of engineered heart muscle 
EHM can be generated from mixtures of PSC-derived cardiomyocytes, inactivated 
NMRI murine embryonic fibroblasts, and rat tail collagen (Didie et al., 2013). In addition 
to contractility measurements in EHM from the newly generated selectable PSC-line 





4.3.1 Contractile parameters of engineered heart muscle 
EHMs were generated from PSC-derived cardiomyocytes supplemented with 30% 
inactivated MEFs. EHMs showed spontaneous contraction after 4 days in culture (one 
day after transferring to stretchers). Isometric force measurements at culture day 10 
demonstrated positive inotropic response to increasing extracellular calcium 
concentrations with maximal contractile force (0.30±0.04 mN; n=7) at 0.8±0.4 mmol/L 
extracellular calcium (Figure 21A). The apparent EC50 for calcium was found to be 
0.4±0.04 mmol/L. Contraction experiments were performed under 4 Hz electrical field 
stimulation in Tyrode’s solution. EHMs showed a slight but not significant positive 
inotropic response to adrenergic stimulation. Subsequent muscarinergic stimulation with 
carbachol elicited a negative inotropic response (Figure 21B). 
           
Figure 21: Contractile properties of PSC-EHM. The ordinates indicate force of contraction (FOC) of 
EHM exposed to increasing extracellular calcium (A) or isoprenaline followed by carbachol stimulation at 





4.3.2 Morphological analysis of engineered heart muscle 
The morphology of cardiomyocytes within the EHM was analyzed by whole mount 
staining of EHM for α-actinin, connexin 43, and cardiac troponin I. Whole mount staining 
of EHMs for α-actinin showed that cardiomyocytes in EHM are anisotropically arranged 
(Figure 22). The EHMs also showed positive staining for the gap junction protein 
connexin 43 in a diffuse pattern along the cell surfaces, providing morphological 
evidence for cardiomyocyte coupling within the EHMs. 
  
 
Figure 22: Morphological characterization of engineered heart muscle. Immunfluorescence stainings 
and confocal microscopy of whole mount EHMs. Immunolabeled structures are indicted in the respective 
panels. DNA (in blue) was labelled with Hoechst. Scale bars: 20 µm 
4.3.3 Immunologically relevant proteins in engineered heart muscle 
EHMs from PSC-derived CMs and inactivated NMRI MEFs were dissociated into single 
cells. Flow cytometry identified 49±3% (n=7) of the cells as α-actinin positive CMs 




         
Figure 23: Cardiomyocyte content in EHM. Representative scatter plot of EHM-derived cells labelled 
with isotype control (A) and α-actinin (B). C. Bar graph summarizes the data obtained from seven EHMs. 
Similarly as for PSC-cells directly from spinner flask cultures, EHM were analysed under 
basal and IFNγ (25 ng/mL; 48 hrs prior to dissociation) stimulated conditions by flow 
cytometry. EHM-derived cells showed no detectable MHC-I (H-2Kd), MHC-II (I-A/I-E), 
CD86, PD-1, and PDL-1 (Figure 24A and 24B). CD40 and CD80 were identified in 
2±0.5% and 7±2.5%. CD1d was detected in 5.5±2.5% of the EHM-cells. IFNγ increased 
the amount of EHM-cells expressing MHC-I (H-2Kd), MHC-II (I-A/I-E), PD-1, and PD-L1 
to 32±1.5%, 1.3±0.3%, 1±0.5%, and 28%. Conversely, CD40 positive cells appeared to 







                      
 
Figure 24: Immunological properties of PSC-EHM derived cells. A and B represent individual 
histograms obtained from EHM derived cells with and without IFNγ exposure (25 ng /ml for 48 hrs); grey 
histogram represent the isotype controls. C-F Bar graphs summarize the flow cytometry data. *p<0.05, 




4.4 Immunological properties of native cardiomyocytes 
After finding surprisingly little MHC-I expression on unstimulated PSC-derived 
cardiomyocytes, we wanted to confirm expression of MHC-I also in cardiomyocytes 
isolated from neonatal (n=1) and adult (n=1) mice. 
4.4.1 Expression of MHC-I on cardiomyocytes from neonatal mice 
Cardiomyocytes were isolated enzymatically from neonatal DBA (H-2d/d) mice (n=1), 
expressing GFP under the control of the alpha myosin heavy chain (MYH6) promoter 
(Figure 25B). The isolated cells were then stained for MHC-I expression and analyzed 
by flow cytometry. 47% of the cardiomyocytes (GFP-positive) were found to be MHC-I 
(H-2Kd) positive (Figure 25A).  
      
Figure 25: MHC-I expression on neonatal mouse cardiomyocytes. A. Flow cytometry analysis for H-
2K
d 
staining on cardiomyocytes derived from DBA neonatal mice. Scatter blot on the left represents 
negative control for GFP; middle plot represents isotype control and the scatter plot on the right 




4.4.2 Expression of MHC-I on cardiomyocytes from adult mice 
After finding high basal MHC-I expression in neonatal mouse cardiomyocytes in 
contrast to PSC-derived CM, we analyzed MHC-expression on adult murine 
cardiomyocytes. 
Cardiomyocytes were isolated from adult αMHC-GFP transgenic DBA mice heart by 
Langendorff perfusion method and seeded on laminin coated cover slips for 24 hours 
with IFNγ treatment. Flow cytometry of adult cardiomyocytes is challenging because of 
their size. Thus the cells were stained after fixation for β-2 microglobulin, a surrogate for 
MHC-I. Adult cardiomyocytes showed very low basal B2M protein abundance, with 
enhanced B2M after IFNγ stimulation (Figure 26). 
 
Figure 26: MHC-I expression on adult mouse cardiomyocytes. Representative immunofluorescence 
stainings for β-2 microglobulin (B2M, red) in adult GFP-positive cardiomyocytes (αMHC-GFP model; 
green). Bar graph summarizing the data from comparative analyses of cardiomyocytes with or without 
IFNγ treatment (25 ng/mL for 24 hrs). Blue: nuclear DAPI staining (* p<0.05 vs -IFNγ, two tailed, unpaired 




4.5 In vitro immunogenicity analysis of PSC-cardiomyocytes 
For the analysis of in vitro immune stimulatory properties of PSCs, we employed a co-
culture system of splenocytes from DBA (H-2Kd/d) and BL6 (H-2b/b) mice with PSC-
derived cells (H-2d/d) and IFNγ treated PSC-derivatives (H-2d/d) to simulate 
“inflammation” in the dish. In this co-culture system the immune cells from a crude or T-
cell selected splenocyte population (responders) are in direct contact with the PSC-
derived cells (stimulators; NM/CM). Activation of lymphocytes results in their 
proliferation and enhanced cytotoxic effects.         
4.5.1 Isolation of T-lymphocytes from spleen 
T-lymphocytes were isolated from mouse spleen by depletion of cells expressing 
CD11b, CD11c, CD19, CD45R (B220), CD49b (DX5), CD105, Anti-MHC-class II, and 
Ter-119(magnetic activated cell sorting method- MACS). After isolation, the cells were 
screened for viability and purity by flow cytometry. Viability was tested by staining with 
sytox and purity by staining for CD3. Flow cytometry data showed that 28% of the 
splenocyte population was CD3 positive (Figure 27A). T-lymphocyte enrichment by 




                     
Figure 27: Assessment of splenocyte identity by flow cytometry. A. Representative histogram-
overlay showing 28% CD3 positive cells in the crude splenocyte populations. B. Bar graph showing the 
percentage of CD3 positive cells before and after MACS enrichment (n=3). C. Gating strategy showing 
the viability (Sytox negative) of the CD3 positive population (middle panel); 98% of the cells from this 
population were identified as CD3 positive T-lymphocytes. Grey filled histograms represents isotype 
controls. 
4.5.2 Validation of immune cell activation assay 
eFluor 670 is a red fluorescent dye that binds unspecifically to intercellular proteins. It is 
very stable and upon cell division is distributed equally between the daughter cells. 
Thus “dilution” of the dye with every cell division can be analysed by flow cytometry 
(Figure 28A), allowing for a precise assessment of proliferative activity over several cell 
divisions (Quah et al., 2007). 
After validation of the assay with T-lymphocytes from Balb/c mice and concanavalin A 
(Con.A) activation (Figure 28A), splenocytes were isolated from BL6 (H-2b/b) and DBA 
(H-2d/d) mice and labelled with eFluor 670. These labelled cells were co-cultured with 




treatment and monitored for cell proliferation as described above. Splenocytes from BL6 
and DBA mice treated with Con.A served as positive controls, showing higher rate of 
cell proliferation compared to all other conditions. Unlabeled cells treated with Con.A 
were investigated to define autofluorescence. eFluor 670 labels cells without Con.A 
treatment served as a baseline fluorescence control. After co-culture of eFluor 670 
labelled splenocytes (responders) with PSC-derivatives (stimulators), the immune cells 
in the splenocytes are activated and proliferated which resulted in the dilution of the dye 
in the splenocytes (the peak observed between the unstained stimulated cells and 
stained unstimulated cells). In the co-culture models; these division peaks were not 
clearly evident likely because of the heterogeneous splenocyte cell population (Figure 
28B). We thus calculated the complete fraction of cells with lower eFluor 670 signal and 
compared it to the high eFluor 670 non-proliferative cell fraction. 
                        
Figure 28: T-lymphocyte proliferation assay. A. Control experiment: treatment of purified eFluor670 
(APC-A) T-lymphocytes isolated from Balb/c spleen with the unspecific T-cell stimulator concanavalin A 
for 4 days resulted in approximately 4 consecutive cell divisions (see peaks in histogram). B. Splenocyte 
proliferation: treatment of eFluor670 (APC-A) labelled splenocytes isolated from spleen with concanavalin 
A for 4 days. Live cells were gated based on cell size (FSC-A) and granularity (SSC-A; left dot plot); 
double positive T-lymphocyte population stained with alexa 594 CD3 (PE-Texas Red-A) and eFluor 670 




4.5.2.1 Strong leukocyte activation by PSC derivatives in monolayer culture 
Under basal conditions, CM and NM enhanced leukocyte proliferation (Figure 29-30). In 
the T-cell enriched populations proliferation was enhanced massively to Con.A control 
levels irrespective of the simulated autograft (DBA model; Figure 29) and allograft (BL6 
model; Figure 30) scenario. IFNγ (25 ng/ml) stimulated cells (48 hours) did not further 
enhance T-cell proliferation. Only in the unselected splenocyte population cultured with 
MHC-mismatching PSC-NM allografts there appeared to be enhanced proliferation 
under IFNγ stimulation (Figure 30B). 
 
Figure 29: In vitro immunogenicity induction by MHC-matched PSC-derivatives. A. Representative 
histogram-overlays of unstained cells, stained unstimulated cells and stimulated cells under different 
conditions. Bar graphs summarizing the data on splenocyte (Spl.) (B) and T-cell (C) proliferation. Con.A 





Figure 30: In vitro immunogenicity induction by MHC-mismatched PSC-derivatives. A. 
Representative histogram-overlays of unstained cells, stained unstimulated cells and stimulated cells 
under different conditions. Bar graphs summarizing the data on splenocyte (Spl.) (B) and T-cell (C) 
proliferation. Con.A Concanavalin A, Spl. Splenocytes.  
4.5.2.2 No leukocyte activation by PSC-engineered heart muscle 
Next, immunogenicity of PSC-EHM was assessed. Similarly as outlined above, eFluor 
670 dye labelled splenocytes from BL6 (H-2b/b) and DBA (H-2d/d) were co-cultured with 
EHMs generated from PSC-CM (B3 line-H-2d/d) and inactivated BL6-MEFs or 
inactivated DBA-MEFs. In addition, EHMs were treated with IFNγ for 48 hours and then 
co-cultured with eFluor 670 dye labelled splenocytes for 4 days. Inclusion of different 
MEFs in the EHM resulted either in a complete MHC match or MHC mismatch for the 
NM-fraction, allowing analysis of different MHC-I match and mismatch combinations 
between CM, NM and responder cells. After 4 days of co-culture, splenocytes were 
collected and measured for cell proliferation by flow cytometry. 
DBA and BL6 responder splenocytes co-cultured with DBA-EHMs and BL6-EHMs did 




match situation. A basal proliferation rate of 20±4.5% with splenocytes and 15±3.5% 
with T-cells was seen in the matched allograft DBA model (Figure 31A-C). Similarly a 
minimal proliferation of 12±3% in splenocytes and 9±2% in T-cells was seen in all the 
mismatch conditions with BL6 splenocytes (Figure 32A-C).  
 
Figure 31: In vitro immunogenicity induction by MHC-matched PSC-EHM. A. Representative 
histogram-overlays of unstained cells, stained unstimulated cells and stimulated cells under different 
conditions. Bar graphs summarizing the data on splenocyte (Spl.) (B) and T-cell (C) proliferation. Data 
from three independent experiments. BL6-EHM: CMs + inactivated BL6-MEFs; DBA-EHM: CMs + 





Figure 32: In vitro immunogenicity induction by MHC-mismatched PSC-EHM. A. Representative 
histogram-overlays of unstained cells, stained unstimulated cells and stimulated cells under different 
conditions. Bar graphs summarizing the data on splenocyte (Spl.) (B) and T-cell (C) proliferation. Data 
from three independent experiments. BL6-EHM: CMs + inactivated BL6-MEFs; DBA-EHM: CMs + 
inactivated DBA-MEFs; with or without IFNγ stimulation: 25 ng/mL for 48 hrs. 
4.5.3 Activation of cytotoxic T-Lymphocytes 
In the previous experiments the stimulation of splenocyte and T-cell proliferation by 
PSC-derivatives in monolayer and EHM co-culture were analysed. Proliferation and 
activation of T-cells can lead to target cell lysis by cytotoxic (CD8 positive) T-cells. To 
investigate if the PSC-derived CMs can induce a cytotoxic reaction we employed a non-
radioactive lactate dehydrogenase (LDH) release assay.  
Briefly in this method, T-cells isolated from BL6 and DBA spleens were co-cultured with 




cells with PSC-CM (Figure 33A). Depending on the amount of lysis, lactate 
dehydrogenase (LDH) is released in to the culture medium. After 4 hrs of co-culture, the 
medium supernatant is removed and the lysis was measured spectrophotometrically at 
490 nm. There was a very low LDH-release with no difference between CM co-cultured 
with MHC-matched (DBA) and mismatched (BL6) T-cells. After IFNγ treatment there 
was a trend towards a higher LDH-release which was more pronounced in the 
mismatch condition (Figure 33B).  
          
Figure 33: Activation of cytotoxic T-lymphocytes by PSC-CM A. Morphology of T-cells, CMs and co-
culture. B. Percentage lysis of the target cells was compared between different conditions. Effector cells 
(T-cells) to target cells (CM) ratio was 10:1. (n=3/group). 
4.6 In vivo immunogenicity analysis of PSC-derivatives 
Finally, we evaluated the immunogenicity of PSC-derivatives (NM/CM) in mice with a 
MHC-match (B6D2F1, H-2b/d; PSC-B3 were derived from B6D2F1 chimeras) and MHC-
mismatch (BL6, H-2b/b) background. B6D2F1 mice were chosen to simulate the 
anticipated clinical scenario of perfect MHC-I matching of PSC-derivatives (H-2d/d) in an 
MHC-mismatch recipient with heterozygote expression from the MHC locus (Didie et al., 




mainly consisting of NMs (Figure 34A) or PSC-derived cardiac bodies mainly consisting 
of CMs (Figure 34B). 
 
Figure 34: Morphological analysis of PSC-derived cardiac bodies and EBs. A. H&E staining for 
cardiac and embryoid bodies. B. Cardiac bodies obtained after selection with G418 were stained for α-
actinin (red) and f-actin (green); nuclei were labelled in blue (DAPI). 
4.6.1 Retention of PSC-derived cardiac body implants 
Implantation underneath the kidney capsule was chosen to evaluate the effect of MHC-I 
match and mismatch on immune cell infiltration. The kidney capsule was chosen as 
implantation site, because of rapid vascularisation and an easy identification of the 
implants even after weeks (Figure 35A). Kidneys were harvested 1, 3, 7, 14, and 28 
days after implantation of cardiac bodies and monitored for graft survival and cellular 
infiltration. Spontaneous contraction could be observed macroscopically until day 3 and 
in one animal until day 28 after implantation under MHC-matched conditions and until 
day 7 under MHC-mismatched conditions (Figure 35). Despite selection to cardiac 





                                                                                             
              
          
Figure 35: Retention of PSC-derived cardiac body implants. A. Macroscopic appearance of a cardiac 
body implant underneath the kidney capsule (immediately after implantation). B. Representative images 
of kidneys implanted with cardiac bodies(H-2
d/d
): upper panels show kidneys harvested from B6D2F1 
mice (H-2
b/d
, MHC-match) at the indicated time points after cardiac body implantation; bottom panels 
show kidneys harvested from BL6 mice (H-2
b/b
, MHC-mismatch) at the indicated time points after cardiac 
body implantation. The site of implantation is highlighted with a black circle. C. Summary of observed 
beating activity of cardiac bodies immediately after harvesting the kidney from MHC-matched and MHC-
mismatched mice on the indicated days. The tick mark () represents a beating graft/mouse and a cross 




4.6.2 Histological analysis 
Kidney explants were subjected to morphological analyses in paraffin sections after 
H&E staining to evaluate the status of inflammation and cellular infiltration after 
implantation in the MHC-match and mismatch conditions. The degree of cellular 
infiltrates after implantation of cardiac bodies in the MHC-match with missing allele 
(B6D2F1) and mismatched (BL6) conditions were similar with low to moderate amounts 
of infiltration at days 7, 14 and 28 after implantation (Figure 36).In contrast, after 
implantation of EBs a high cellular infiltration could be observed within 7 days after 
implantation in both matched and mismatched conditions. At day 14 and day 28 the EB 











     
Figure 36: H&E staining of kidney sections implanted with cardiac bodies. A. Upper panels show 
kidneys harvested from B6D2F1 mice (H-2
b/d
, MHC-match) at the indicated time points after cardiac body 
implantation (H-2
d/d
). The lower panel show kidneys harvested from BL6-J mice (H-2
b/b
, MHC-mismatch) 
at the indicated time points after implantation. K: kidney; G: graft. B. Summary of morphological findings 
with a focus on inflammatory responses i.e., round cell infiltration, in MHC-matched implants (in B6D2F1 
mice) and MHC-mismatched implants (in BL6-J mice) at the indicated time points after implantation; semi 





       
Figure 37: H&E staining of kidney sections implanted with embryoid bodies. Upper panels show 
kidneys harvested from B6D2F1 mice (H-2
b/d
, MHC-match) at the indicated time points after EB 
implantation (H-2
d/d
). Lower panels show kidneys harvested from BL6-J mice (H-2
b/b
, MHC-mismatch) at 
the indicated time points after EB implantation (H-2
d/d)
). K: kidney; G: graft. B. Summary of morphological 
findings with a focus on inflammatory responses, i.e., round cell infiltration, in MHC-matched EB implants 
(B6D2F1 mice) and MHC-mismatched EB implants (in BL6-J mice) at indicated time points after 







The largely haploidentical genome of parthenogenetic stem cells, generated by artificial 
activation in MII oocytes (Figure 5C), makes them immunologically attractive for cell 
based organ repair applications. MHC-haploidentical cells may be applicable broadly 
with minimal transient or even without immune suppression as allografts in MHC-
matched recipients (Nakajima et al., 2007; Taylor et al., 2005). In this study we 
generated a novel transgenic H-2 haploidentical PSC line carrying a NeoR gene 
expressed under the control of the cardiomyocyte restricted α-myosin heavy chain 
(MYH6) promoter (Klug et al., 1996). Bioreactor protocols for scalable cardiomyocyte 
differentiation as well as selection and subsequent application in myocardial tissue 
engineering were established. As to their immunological properties, we found that PSC-
derived cardiomyocytes (CM) exhibited little to no MHC-I and MHC-II, little to no CD40 
and CD86 as well as little to no PD-L1 and PD-1, but notable CD80 and CD1d 
expression under basal conditions. PSC-derived non-myocytes (NM) showed little to no 
MHC-II, little to no CD40, CD80, and CD86 as well as little to no PD-L1 and PD-1, but 
notable MHC-I and CD1d expression under basal conditions. Simulated “inflammation” 
by stimulation with IFNγ increased MHC-I, MHC-II, and PD-L1 in all investigated cells. 
CD86 was enhanced in PSC-derived NMs under IFNγ in 1 out of 3 experiments. 
Interestingly, transient IFNγ resulted in sustained activation of MHC-I in PSC-derived 
CMs and NMs. PSC-EHM were in general less susceptible to IFNγ with only enhanced 
MHC-I and PD-L1. In a mixed lymphocyte reaction type experiment, massive 
lymphocyte activation by autologous or allogeneic PSC-derivatives was observed in 
monolayer culture. Conversely, no lymphocyte activation under basal and IFNγ 
stimulated conditions was observed in EHM culture. Finally, cytotoxicity appeared to be 
enhanced in a simulated allograft scenario. Implantation of PSC-CM and PSC-NM (H-
2d/d) under the kidney capsule in two allogeneic mouse models with a MHC-match (H-
2b/d) and a complete MHC-mismatch (H-2b/b) showed no obvious difference in immune 
cell infiltration (implant study for 4 weeks). However, in one mouse with a MHC-matched 




notion that PSC-derivatives are not immunologically naive, but may be suitable for 
MHC-matching without immune suppression 
5.1 Generation and differentiation of a neomycin selectable PSC line 
A selectable marker gene (NeoR) was introduced into the B3 PSC line with confirmed 
haploidentity in the H-2 locus. Although derived from B6D2F1 chimeras this line 
expresses only the DBA H-2-haplotype H-2d/d. Haploidentity is a common feature in 
PSC-lines, rendering them potentially advantageous for allograft applications with MHC-
matching (Didie et al. 2013). We chose a NeoR as a well-established selectable marker 
gene under transcriptional control by the cardiomyocytes-specific alpha myosin heavy 
chain (MYH6) promoter. MYH6 is detectable early in the developing heart in vivo and it 
is specific for cardiomyocytes in differentiating ES cells (Boheler et al., 2002; Gulick et 
al., 1991). After successful integration of the αMHC-NeoR transgene into the B3-PSC 
line, a spinner flask suspension culture was established to allow scaling of 
cardiomyocyte differentiation. In the presence of G418 spontaneously beating EBs 
could be converted into cardiac bodies comprised of >90% cardiomyocytes. This was in 
line with the original description of this selection procedure in mouse embryonic stem 
cells (Klug et al., 1996) and our recent study on the genetic manipulation of PSCs using 
a similar strategy (Didie et al., 2013). In spinner flasks we succeeded to produce 25±5 x 
106 cardiomyocytes from 10 x 106 input PSCs. We have not attempted to apply directed 
differentiation (Kattman et al., 2011) or metabolic (Tohyama et al., 2013) selection 
which may achieve similar numbers and purity without the need for genetic 
manipulation. These protocols are well established in human models, but so far not 
used widely in the mouse. For a clinical approach it is very important to generate a pure 
population of cardiomyocytes from any stem cell source, since after implantation the 
presence of proliferating stem cells might lead to the formation of teratoma. It was 
shown that as few as 1950 pluripotent stem cells can lead to teratoma formation 




5.2 Immunologically relevant proteins on PSC-derived cardiomyocytes and non-
myocytes 
PSC and PSC-derivatives have unique immunological properties because they are 
typically homozygous at the MHC locus (Didie et al., 2013). This is because the MHC 
locus in mouse and human is located near the centromere and thus does typically not 
crossover during meiosis (Revazova et al., 2008). There is very little information 
available on the expression of immunologically relevant molecules on PSC-derivatives. 
Thus we assessed the expression of MHC-I, MHC-II, CD-40, CD-80, CD-86, CD1d, PD-
L1 and PD-1 in cardiomyocytes (CM) and non-myocytes (NM) derived from the H-2d/d 
B3 line. NMs showed significant expression of MHC-I and CD1d, whereas CMs showed 
no expression MHC-I, MHC-II but CD80 and CD1d expression was observed under 
basal conditions. This argues for low MHC-related immunogenicity of CM. In order to 
mimic inflammatory conditions that generally occur during cardiovascular diseases like 
myocardial infarction or viral myocarditis, PSC-NM and PSC-CM were treated with 
IFNγ. After IFNγ stimulation, MHC-I (H-2Kd), MHC-II (I-A/I-E) and PD-L1 were 
upregulated significantly in PSC-NM and PSC-CM. This data is in accordance with 
observations in ESC derivatives (Bonde and Zavazava, 2006; Lampton et al., 2008). 
The demonstration that MHC-I is expressed in CM under IFNγ stimulation did however 
suggest that immunological competence may be achieved quickly under in vivo 
conditions. Up-regulation of MHC-I expression after IFNγ treatment was persistent; 
suggesting that PSC-derivatives, once immunologically challenged, obtain sustained 
MHC-I (H-2Kd) with associated immunogenicity.  
The expression levels of immunological molecules such as MHC-I, MHC-II and co 
stimulatory molecules (CD80, CD86, CD40) was very low in undifferentiated PSC which 
was hardly influenced by IFNγ treatment. It has been shown that human ES cells 
express MHC-I proteins in very low levels (Suarez-Alvarez et al., 2010). Although most 
somatic cells express high levels of MHC-I, the in vitro and in vivo differentiated 
derivatives of human ESCs apparently retain a low level of MHC-I expression. 
Consistent with our data, addition of IFNs in particular IFNγ to the growth media of 




(Drukker et al., 2002). In NM we observed high (35% of all PSC-NM) expression of 
MHC-I under basal conditions which could be increased to nearly 100% after IFNγ 
treatment. Consequently, it may be anticipated that NMs trigger rejection more strongly 
than CMs. 
When T-cells recognize mismatched antigen presented by either a donor or recipient 
APC, a signal is delivered to the T-cell via the TcR/CD3 complex.  Immediately a 
second co-stimulatory signal is received that activates the T-cell, triggering it to divide or 
proliferate to differentiate and communicate with other leukocytes that can then 
participate in the rejection response. This second signal is delivered for CD4+ T-cells 
when a co-stimulatory B7.1 (CD80) molecule on the APC binds with the CD28 receptor 
on the T-cell. On the other hand CD8+ T-cells receive their co-stimulation and definitive 
activation by helper T-cells. An absence of co-stimulation will render a T-cell anergic, 
i.e., non-responsive to further stimulation by the antigen (Boyd et al., 2005). In this study 
we could detect only a very low expression of co-stimulatory molecules (CD40, CD80 
and CD86) on PSC-NM and PSC-CM even after IFNγ stimulation. Theoretically this 
should ameliorate or completely inhibit a rejection of PSC-derivatives in vivo despite 
MHC-I expression.  
CD1d molecule was significantly expressed at basal conditions on PSC-derivatives and 
was not altered after IFNγ treatment. CD1d is a non classical MHC-I like molecule 
generally expressed on thymocytes, dendritic cells, activated monocytes and B 
lymphocytes. It is also expressed on T-cells and non-haematopoetic cells like CMs and 
endothelial cells, CoxsakievirusB3 (CVB3) myocarditis infections can enhance CD1d 
expression (Liu and Huber, 2011). NKT-cells kill CVB3 infected CD1d positive CMs in a 
Fas-dependent manner, which aids in viral control by eliminating infected cells early in 
the virus replication cycle (Huber, 2005). In a mouse model of CVB3 induced 
myocarditis, an infection activates heart-specific, autoimmune CD8+ cytolytic T-
lymphocytes (NKT cells) (Guthrie et al., 1984; Huber and Lodge, 1984) which kill 
uninfected cardiomyocytes through recognition of cardiac myosin epitopes. All this data 
suggests that expression of CD1d on cardiomyocytes might activate the NKT cells 




derived cells was low compared to its expression on PSC-CM in a monolayer culture 
suggesting a low propensity for NKT cell activation. 
An important mechanism regulating the peripheral tolerance and autoimmunity is the 
expression of programmed death-1 (PD-1) receptor (Francisco et al., 2010; Tarrio et al., 
2012). Binding of PD-1 to its ligand programmed death ligand 1 (PD-L1) results in the 
upregulation of suppressive functions such as T-cell anergy or stimulation of Tregs in 
the immune system. PD-L1 is broadly expressed on hematopoietic cells and non-
hematopoietic cells such as vascular endothelial cells, epithelial cells, muscle cells, 
hepatocytes, placental cells and islet cells (Riella et al., 2012). Myocardial injury is 
associated with up regulation of endogenous inflammatory mechanisms (Baban et al., 
2014). It has been shown that expression of PD-1 and PD-L1 were significantly 
increased in the ischemic-reperfused heart (Baban et al., 2015). PSC-derived CMs 
showed an upregulation of PD-L1 after IFNγ stimulation. In contrast PD-1 expression 
was not observed even after IFNγ stimulation. Absence of PD-1 and presence of PD-L1 
on PSC-CM might have important role in the immunoregulatory mechanism of CMs and 
lead to an immune suppressive effect of cardiomyocytes. 
5.3 Expression of immunologically relevant molecules in EHM  
Expression of immunological molecules MHC-I, MHC-II, CD40, CD80, CD86 and CD1d 
was studied on EHM derived PSC-CM. EHMs were generated from 70% PSC-CM and 
30% NMRI MEF and showed functional properties similar to native myocardium. With 
respect to adrenergic stimulation with isoprenaline the EHM derived from PSC30B3 cell 
line did not show any significant effect in contrast to the EHM made from PSCA3 (Didie 
et al., 2013). The positive inotropic response of cardiomyocytes after beta-adrenergic 
stimulation increases in parallel with a maturation of the cells. Thus CMs derived from 
PSCA3 might be more matured compared to CMs derived from PSC30B3. However 
immunofluorescence staining for α-actinin and troponin I after additional 7 days of 
culture under constant load demonstrated the presence of well developed 
cardiomyocytes with regular sarcomeric cross-striations and expression of gap-junction 




differentiate and mature in an organotypic manner in engineered heart tissue model with 
time (Tiburcy et al., 2011). With this information one can assume that PSC-CM might 
also immunologically mature in the EHM model. PSC-CMs in EHM showed negligible 
expression of MHC-molecules and co-stimulatory molecules. Even after IFNγ 
stimulation only MHC-I and PD-L1 was significantly up regulated and other molecules 
were unchanged. Taken together, we assume that lack of MHC-II expression on EHM 
derived cells argues for the immunological maturity of PSC-CM in EHM model.  
5.4 MHC-I expression on neonatal and adult heart cardiomyocytes 
After finding low MHC-I expression on PSC-CM we were investigating if this is a feature 
of PSC-derived CM or if it is a general characteristic of CM. To this means we stained β-
2 microglobulin on adult CM. The rationale for choosing β-2-microglobulin for 
immunofluroscence was because there is no optimal antibody available for staining of 
MHC-I (H-2Kd) in fixed cells and tissue samples and because β-2 microglobulin is a 
component of MHC-I molecules. Staining for β-2 microglobulin after IFNγ stimulation 
showed that this protein was mostly localized surrounding the nucleus with a spotty 
appearance through put the cell. β-2 microglobulin is processed in the endoplasmic 
reticulum before it is transported to the membranes (Dargemont et al., 1991). Better 
resolved microscopy would need to be performed to identify whether the spotty β-2 
microglobulin signals are located at the outer cell membrane including its invaginations 
(t-tubules). In line with our in vitro observation Rose et al. showed that normal 
myocardium does not express MHC-antigens, however after transplantation MHC-I 
antigens can be induced (Rosa and Fellous, 1988). Wang et al. showed that hESC cells 
lacking β-2 microglobulin show reduced killing by CD8+ T-cells (Wang et al., 2015). 
Two fold recognition of MHC-I and MHC-II antigens is necessary for activation by 
cytotoxic T-cells for lysis of virus-infected cells and cells bearing alloantigens 
(transplanted cells) (Zinkernagel and Doherty, 1979). The MHC-II antigens are involved 
in cellular communication that regulates the immune response. These antigens are 
found primarily on interstitial dendritic cells in the heart (Daar et al., 1984). It was 




antigens and do not have detectable levels of MHC-II antigens (Seko et al., 1990). 
Endothelial cells lining the microvasculature might express both MHC-I and MHC-II 
antigens (Rose et al., 1985). In conclusion these findings might explain why the heart is 
relatively resistant to organ rejection after transplantation and why the chronic rejection 
after heart transplantation is mainly directed against the vasculature. 
5.5 In vitro immunogenicity of PSC-derived cardiomyocytes and non-myocytes 
In order to study the susceptibility of PSC-derivatives to elicit an immune reaction, we 
employed in vitro proliferation assay. In this assay haploidentical PSC-NM (H-2d/d) and 
haploidentical PSC-CM (H-2d/d) were co-cultured with labeled splenocytes from related 
MHC-match DBA (H-2d/d) and unrelated MHC-mismatch BL6 (H-2b/b) mice. Many groups 
have used [3H] thymidine labeling of cells for measuring the proliferative response of 
responder cells (splenocytes). We attempted to label CMs with [3H] thymidine and 
encountered problems with background release, which required the use of an 
alternative method (eFluor 670 labeling). The use of fluorescence cell labeling for cell 
migration and proliferation under in vitro and in vivo conditions has been shown by 
many groups, it was also demonstrated that these fluorescent dyes show low variance 
and low toxicity (Quah and Parish, 2012; Quah et al., 2007). 
Proliferation of the T-lymphocyte population from the splenocytes was investigated by 
staining with CD3. In the MHC-match condition PSC-NM and PSC-CM show a similar 
degree of splenocytes and T-lymphocytes activation (35±3% and 55±3%); IFNγ did not 
enhance lymphocyte proliferation. This data suggests that upregulation of MHC-I, MHC-
II after IFNγ stimulation does not have any effect in stimulating the proliferation of MHC- 
matched splenocytes or T-lymphocytes in vitro. Poor resolution of division peaks in the 
co-culture set up might be because of heterogeneous responders (splenocytes) 
population, whereas pure T-lymphocytes stimulated with mitogen concanavalin A (Con. 
A) showed clear division peaks (Figure 29A). 
In MHC-mismatch condition BL6 (H-2b/b), splenocyte proliferation appeared to be 




effect on proliferation of splenocytes and T-lymphocytes with IFNγ treatment. Our data 
is in accordance with Malliaras et.al where they have showed that allogeneic rat 
cardiosphere derived cells (CDCs) elicited negligible lymphocyte proliferation 
comparable to that seen with syngeneic CDCs (Malliaras et al., 2012). In contrast it has 
been demonstrated that undifferentiated syngeneic iPSC and their derivatives lack 
immunogenicity in vitro, whereas with allogeneic iPSC and their derivates a strong 
stimulation to proliferation was observed (Guha et al., 2013). Baban et al. showed that 
cells prepared from normal hearts increased T-cell proliferation suggesting their role in 
antigen presentation, whereas ischemic reperfused cardiac cells significantly reduced 
the percent of proliferating T-lymphocytes which can be reversed by treatment with PD-
L1 blocking antibody (Baban et al., 2015). However, we did not find significant 
differences in PD-L1 expression between PSC-CM and PSC-NM. H-2Kb specific T-cells 
analyzed in the spleen after 25 days of post transplantation with heart allograft showed 
that ~50% of carboxyfluorescein succinimidyl ester (CFSE) labeled T-cells divided six 
times in response to the graft. These H-2Kb specific T-cells that responded to the graft 
showed characteristics of memory cells and were capable of producing IL-2 and IFNγ 
on restimulation (Jones et al., 2001). Finally, splenocytes obtained from a mouse which 
is pre-sensitized with PSC-derivatives might be immunologically more active and might 
show an immune reaction. Taken together, our in vitro proliferation data suggests that 
PSC-CM exhibit a limited effect on splenocyte and T-lymphocyte proliferation from 
MHC-match (DBA) and MHC-mismatch conditions (BL6). 
In this study we show that DBA (H-2d/d) splenocytes and T-lymphocytes after co-culture 
with EHM generated from PSC-CM (H-2d/d) and DBA-MEF (H-2d/d) as well as EHM 
made with PSC-CM (H-2d/d) and BL6-MEF (H-2b/b) show an average proliferation rate of 
15±10%, MHC-I upregulation in the EHM after IFNγ has no effect on the immune cell 
proliferation rate. Also an MHC-mismatch of the MEFs failed to stimulate the 
proliferation of splenocytes and T-lymphocytes. This might be either because of less 
duration of co-culture of EHMs and splenocytes (4 days) or improper contact of 
responder (splenocytes/T-lymphocytes) and stimulator (CM/MEF) cells or lack of 




splenocytes and T-lymphocytes were co-cultivated with DBA-EHM (with DBA-MEF) and 
BL6-EHM (with BL6-MEF) with an average proliferation rate of 10±5%. The rationale 
behind using MHC-matched and –mismatched MEFs was because we know from 
studies in our group that for the successful generation of EHM, non-myocytes are 
essential. Non-cardiomyocytes can be allogeneous, e.g. PSC-derived, but also easily 
generated autologously, e.g. by generating fibroblasts from skin-biopsies, in a clinical 
application. 
Pluripotent stem cell derived cells stimulated with IFNγ present MHC-I antigens on their 
cell surface, these antigens with specific peptide interact with cytotoxic T-lymphocytes 
(Varda-Bloom et al., 2000). To confirm that cytotoxic lymphocytes are involved in lysis 
of PSC-CM we used non radioactive method of cytotoxicity measurement. Our results 
suggested that the killing of PSC-CMs by CTLs was negligible (10%) even after IFNγ 
stimulation in the complete MHC-mismatch condition (BL6). This data contradicts with a 
study where murine ESCs are lysed by allogeneic CTLs after treating the ESCs with 
IFNγ (Bonde and Zavazava, 2006). It has been shown that susceptibility to lysis of the 
ESC derivatives could be increased through pre-incubation with IFNγ for 48 hrs, the 
resulting lysis efficiency was however lower than lysis of normal fibroblasts (Kadereit 
and Trounson, 2011). This data strongly confirms that PSC-CMs have immune 
privileged properties under normal conditions. 
5.6 In vivo immunogenicity of PSC-derived cardiomyocytes and non-myocytes 
In this study we investigated the immunological tolerance of PSC-CM (H-2d/d) after 
allograft implantation in MHC-matched (B6D2F1, H-2d/b, with missing allele) and MHC-
mismatched (BL6, H-2b/b) mouse models under the kidney capsule. The rationale 
behind choosing kidney as the site of implantation was because it is easily accessible 
and transplanted EBs are well contained under the kidney capsule in a highly 
vascularized site (DeWard et al., 2014). Many groups have shown that cells injected 
directly into myocardium are mostly lost in the blood circulation and their viability is 
highly compromised (Paulis et al., 2013; Roell et al., 2007). PSC-CM implanted under 




implantation suggesting immune resistance. A minimal amount of cellular infiltration was 
observed in the initial time intervals (day 1, day 3, day 7) in haematoxylin and eosin 
staining suggesting this inflammation might be because of the surgery procedure. In 
one of the three MHC-match mice implanted with PSC-CM at day 28, teratoma formed 
indicating the presence of proliferating cells even after CM-purification. This data is in 
accordance with Hentze et al. where they observed that ESC differentiated cells even 
after extended culture time formed teratoma in mice (Hentze et al., 2009).This might be 
a major limitation when using stem cell derived-CMs for clinical applications. 
T-cells, B cells and macrophages have been shown to infiltrate teratomas in syngeneic 
mice (de Almeida et al., 2013). Although they were incapable of preventing tumor 
growth, these lymphocyte infiltrates did reduce tumor appearance (Dressel et al., 2008). 
It was demonstrated that when a small number of syngeneic ES cells were implanted, 
teratomas were not formed. Implantation of 5 x 105 undifferentiated or differentiated 
syngeneic ES cells has been shown to result in teratoma formation in 33% and 17% of 
recipients respectively. However, implantation of high numbers of undifferentiated or 
differentiated cells (2 x 106) produced teratoma formation in 100% of recipients (Dressel 
et al., 2008; Lee et al., 2009). From this data one can assume that when low numbers of 
cells are implanted, cells either die instantly after transplantation or are rejected. 
In the MHC-mismatch (BL6, H-2b/b) setting, after implantation of PSC-CM (H-2d/d) under 
the kidney capsule, beating was noticed until day 7. No beating cells were observed 
after 28 days. These especially need to be repeated to finally draw a conclusion as to 
the immune privilege of PSC-derivatives in vivo. The results from the implantation data, 
where PSC-NM implanted under the kidney capsule have shown similar results to that 
of PSC-CM in MHC-match (B6D2F1, H-2b/d) and strong rejection in MHC-mismatch 
(BL6, H-2b/b) mouse models. Implantation of PSC-NM in the MHC-match setting showed 
significant cellular infiltration until 7 days of implantation. This might be either because 
the in vitro maintenance of PSC-NM might have altered the immunological property or 
the surgical procedure, which has to be further evaluated with further animal 
experiments. In the MHC-mismatch setting high cellular infiltration was also observed 




and killed after 28 days of implantation. Very few of the implanted cells remained after 4 
weeks of implantation in the allogeneic setting. This suggests that significant amount of 
MHC-I expression on PSC-NM, results in the development of a strong immune rejection 
in the allogeneic setting. In contrast to our data, it was also reported that male EBs 
implanted under the kidney capsule of female mice survived indefinitely despite of 
occurrence of T-cells specific for mH antigen (Robertson et al., 2007). 
In contrast it has been shown that induction of MHC-I expression by the use of IFNγ 
under in vitro condition improve the subsequent survival and immune integration of ESC 
derived vascular progenitor cells in the syngeneic setting (Ma et al., 2010). It has also 
been demonstrated that the immunogenicity of iPSC derived tissues is comparable to 
that of ESC derived tissues in murine models; terminally differentiated cells from iPSC 
show limited immune response in vivo (Araki et al., 2013). In contrast, other group 
demonstrated that iPSC-derived CMs transplanted in the myocardium of syngeneic 
mice were rejected; they also show that immunogenicity of iPSC-derivatives was 
increased after differentiation (Liu et al., 2013b). Recently it was shown that 
cardiomyocytes derived from MHC-homozygous iPSC exhibited reduced allogeneic 
immunogenicity in MHC-matched non-human primates (Kawamura et al., 2016). In 
contrast to the above data shown, it was reported that co-transplantation of dendritic 
cells along with iPSC derived grafts under kidney capsule results in the immune 
rejection of iPSC grafts (Todorova et al., 2015). Many groups have shown that dendritic 
cells with immature phenotype (low expression of MHC-II molecules and co-stimulatory 
molecules like CD40, CD80, CD86) can induce anergic state in T-lymphocytes 
(Lipscomb and Masten, 2002; Lutz and Schuler, 2002; Lutz et al., 2000), so these 
immature cells when implanted along with the grafts might prolong the survival of the 
graft. 
 




Based on the results obtained in this study we can conclude the following points. 
 Parthenogenetic stem cells can be successfully differentiated into 
cardiomyocytes in large scale using suspension spinner flask culture. 
 Parthenogenetic stem cell derived cardiomyocytes do not express MHC 
molecules (MHC-I and MHC-II) until they are stimulated with IFNγ.  
 Engineered heart muscle can be generated from PSC-derived cardiomyocytes. 
 Immunological maturation of PSC-derived CM in relation to their MHC-II 
expression was observed in EHM model. 
 PSC-derived cells activate lymphocytes under MHC-match and MHC-mismatch 
settings. 
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8.1 Appendix 1 (Supporting Information) 
 
                        
A1.1: Pluripotency markers expression on PSC by flow cytometry. A. Histogram- 
overlay showing the expression of Oct3/4 on PSC at passage p21. B. Histogram-
overlay showing the expression of SSEA-1on PSC. Grey filled histogram represents 
isotype control (IgG).       
   
A1.2: Expression of HLA-ABC molecules on human iPSC. Histogram-overlay of 






8.2 Appendix 2 (Reagents) 
For cloning 
1X TAE-buffer                         mM 
Tris-Acetate                            40 
Sodium-Acetate                      20 
EDTA, pH 7.5                          1 
LB-agarose plate (with ampicillin) 
Agar                                                                               7.5 g 
LB-medium                                                                    500 ml 
Ampicillin stock (100 mg/ml)                                          500 μl 
The LB-agar was autoclaved. After cooled down to around 60°C, LB-agar was poured 
into 10-cm petri dishes. Plates were stored at 4°C after the agar has hardened. 
LB-medium 
Bacto-Tryptone                                                                10 g 
Bacto Yeast Extract                                                         5 g 
NaCl                                                                                10 g 
Chemicals were dissolved with 950 ml of ddH2O and pH was adjusted to 7.4 with 0.1 N 
NaOH. Final volume was brought up to 1 liter and medium was autoclaved. Medium can 
be kept at 4°C for 3 weeks. 
Ampicillin stock (100 mg/ml) 
500 mg of Ampicillin was dissolved in 5 ml of ddH2O. The stock solution was stored at -




Reagents and solutions for isometric force measurement 
For making Tyrode’s working solution, the following stock solutions should be prepared: 
CaCl2 stock (2.25 M) 
CaCl2 x 2 H2O (Mw = 147.02)                                  165.57 g 
ddH2O                                                                       500 ml 
MgCl2 stock (1.05 M) 
MgCl2 x 6 H2O (Mw = 203.01)                                 106.83 g 
ddH2O                                                                       500 ml 
Stock I: Ca2+ concentration in stock I can be adjusted accordingly. 
[Ca2+] (mM)                                      1.8           0.4              0.2 
NaCl (Mw = 58.44)                          175 g       175 g          175 g 
KCl (Mw = 74.58)                            10 g         10 g            10 g 
CaCl2 stock                                     20 ml       4.44 ml       2.22 ml 
MgCl2 stock                                    25 ml        25 ml         25 ml 
Make up with ddH2O to                 1000 ml    1000 ml      1000 ml 
Stock II 
NaHCO3 (Mw = 84.01)                                                  50 g 
ddH2O                                                                          1000 ml 
Stock III 
NaH2PO4 (Mw = 137.99)                                              5.8 g 
ddH2O                                                                           1000 ml 





Tyrode’s working solution (for 8 EHMs) 
Stock I                                         80 ml 
Stock II                                        76 ml 
Stock III                                       20 ml 
Glucose                                       2 g 
Ascorbic acid                              100 mg 
H2O to                                         2 liters 
Reagents for the isolation of Adult mouse cardiomyocytes by Langendorff 
method 
1.Perfusion buffer in mmol/L: 113 NaCl, 4.7 KCl, 0.6 KH2PO4, 0.6 Na2HPO4x2H2O, 
1.2 MgSO4x7H2O, 12 NaHCO3, 10 KHCO3, 10 HEPES, 30 taurine, 10 2,3- 
butanedione-monoxime, 5.5 glucose, 0.03 phenol red, pH 7.4 in H2O. 
2. Liberase DH solution (4.2 mg/ml): 50 mg of Liberase DH were dissolved in 12 ml of 
sterile water, reconstituted on ice for 20 minutes and stored in 150 µl aliquots at -20°C. 
3. Digestion buffer: 30 ml of the perfusion buffer were supplemented with 12.5 µmol/l 
CaCl2, 150-450 µl of Liberase solution, and 300 µl of 2.5 % trypsin solution. Enzymes 
were added straight before use. 
4. Stopping buffer 1: 2.5 ml perfusion buffer supplemented with 50 µmol/l CaCl2 and 1 
% bovine serum albumin (BSA). 
5. Stopping buffer 2: 10 ml perfusion buffer supplemented with 37.5 µmol/l CaCl2 and 
0.5 % bovine serum albumin (BSA). 
6. Culture medium: Minimum essential medium (MEM) supplemented with 0.1 % BSA,                                                                                                                                                                  
2 mM L-glutamine, 10 mM BDM, antibiotics (100 U/ml Penicillin, 100 µg/ml 




Cell culture Medium: 
MEF Medium: DMEM (Gibco # 61965), 10% FCS, 2 mmol/L L-glutamine,1% non 
essential aminoacids (NEAA), 100 U/ml Penicillin und 100 μg/ml Streptomycin. 
Freezing medium: 80% FBS,20% DMSO. 
SC medium: DMEM (Gibco #42430), 15% FCS, 1.000 U/ml LIF,2 mmol/L L-Glutamine, 
1 x NEAA, 50 U/ml Penicillin, 50 µg/ml Streptomycin, 1 mmol/L Na+-Pyruvate, 1X 
Nucleoside mix ( in µmol/L: 30 adenosine, 30 guanosine, 30 cytidine, 30 uridine, 10 
thymidine) and 100 µmol/L 2-mercaptoethanol. 
Differentiation medium: Iscove Medium (Biochrom #F0465), 20% FCS, 2 mmol/L L-
glutamine, 1% NEAA, 100 U/ml Penicillin(P), 100 μg/ml Streptomycin(S), 100 μmol/L 2-
mercaptoethanol, 0.02 mmol/L L-ascorbic acid 2-phosphate sesquimagnesium salt 
hydrate (sigma). 
RPMI medium: RPMI with Glutamax(Gibco), 10% heat inactivated FCS, 100 U/ml 
penicillin, 100 μg/ml streptomycin,100 μmol/L 2-mercaptoethanol, 











A2.1 List of primers 




D17Mit178 For: 5'-ACACAATTTCTTTTAGTGGGTTCC -3' 56 144(b/b)/















Oct3/4 For: 5’-GCCCCAATGCCGTGAAG- 3’ 59 101 
Rev: 5’-CAGCAGCTTGGCAAACTGTTC- 3’ 
Nanog For: 5’-TGCTACTGAGATGCTCTGCACA- 3’ 59 71 
Rev: 5’-TGCCTTGAAGAGGCAGGTCT- 3’ 
Sox2 For: 5’-GGCAGCTACAGCATGATGCAGGAGC- 
3’ 
60 131 
Rev: 5’-CCTGCAGTACAACTCCATGACCAG- 3’ 
Rex-1 For: 5’-GGCCAGTCCAGAATACCAGA- 3’ 59 232 
Rev: 5’- GAACTCGCTTCCAGAACCTG - 3’ 
GAPDH For: 5’-ATGTTCCAGTATGACTCCACTCACG- 3’ 60 171 
Rev: 5’- TGTCGTGGAGTCTACTGGTGTCTTC -
3’ 
 
A2.2 List of primary antibodies 
Antibody Dilution Company clone 
PE anti mouse CD1d 1:100 Biolegend 1B1 
PE anti mouse H-2Kd 1:100 Biolegend SF1-1.1 
PE anti mouse H-2Kb 1:100 Biolegend AF6.88.5 
Alexa Fluor 594 anti 
mouse CD3 
1:100 Biolegend 17A2 
Alexa Fluor 488 anti 
mouse CD3 
1:100 Biolegend 17A2 
FITC Hamster anti mouse 
CD40 
1:100 Biolegend 3/23 
PE anti mouse CD86 1:100 Biolegend GL-1 
FITC anti mouse CD 80 1:100 Biolegend 16-10A1 





PE anti mouse CD274(B7-
H1,PD-L1) 
1:100 Biolegend 10F.9G2 
FITC anti mouse 
CD279(PD-1) 
1:100 Biolegend 29F.1A12 





Anti cardiac Troponin I 1:500 abcam ab47003 
β- 2-Microglobulin 1:250 abcam EP2978Y 
Myosin heavy chain 1:500 DSHB MF20 
Connexin 43 1:250 BD pharmingen 610062 
 
A2.3 List of isotype controls 
Isotype Controls Dilution company clone 
PE Rat IgG2b, k 1:100 Biolegend RTK4530 
PE mouse IgG2a, k 1:100 Biolegend MOPC-173 
PE Mouse IgG2b, k 1:100 Biolegend MPC-11 
Alexa Fluor 488 Rat 
IgG2b, k 
1:100 Biolegend RTK4530 
FITC Rat IgG2a, k 1:100 Biolegend RTK2758 
PE Rat IgG2a, k 1:100 Biolegend RTK2758 
FITC Armenian 
Hamster IgG 
1:100 Biolegend HTK888 
Mouse IgG1 1:250 R&D systems MAB002 
Rabbit IgG 1:2000 sigma I5006 
 
A2.4 List of secondary antibodies 
Secondary 
Antibody 
Dilution Species Company 
Anti-mouse IgG 
Alexa 488 
1:1000 Goat Invitrogen 
Anti-mouse IgG 
Alexa 546 
1:1000 Goat Invitrogen 
Anti-mouse IgG 
Alexa 633 
1:1000 Goat Invitrogen 
Anti-rabbit IgG 
Alexa 488 
1:1000 Goat Invitrogen 
Anti-rabbit IgG 
Alexa 546 
1:1000 Goat Invitrogen 
Anti-rabbit IgG 
Alexa 633 




A2.5 List of fluorescent labels 
Label Concentration Target Company 
DAPI 0.1 µg/ml DNA sigma 
Hoechst 1 µg/ml DNA BD biosciences 
Phalloidin 488 300 units f-actin Invitrogen 
Phalloidin 546 300 units f-actin Invitrogen 
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Current position: (Since May 2011)       
Graduate student at Department of Pharmacology and Toxicology, University Medical 
Center Göttingen, Georg-August-University, Göttingen, Germany.Working on the project 
titled “Immunological properties of parthenogenetic stem cell derived cardiomyocytes 
and their application in cardiac tissue engineering”.  Supervisor: Prof. Wolfram-
Hubertus Zimmermann. 
Research Experience 
Frontier lifeline Pvt.LTD (K.M.Cherian Heart foundation)                    Chennai 
Scientist, Dept of Tissue engineering and stem cell biology     June 2007- March 2011 
 Investigation on scaffold generation for heart tissue repair. 
 Research focus on “Electrospun Polymeric Nanofiber Reinforced Processed 
Porcine Pulmonary Xenograft as a Versatile Conduit in Cardiovascular Surgery”. 
 Worked on “Characterization and optimization of homografts and xenografts for 
heart tissue repair”. 
Indian Institute of Technology Madras (IIT M)                                     Chennai 
Under the supervision of Prof. Dr. Mukesh Doble   May 2006- June 2007 
 Master Thesis entitled “Physicochemical and biocompatible characterization of 










Medical biotechnolgy IIT Madras, Chennai 2005-07 
Masters of Science 
 




Bachelor of Science Microbiology, 
Biochemistry, Chemistry 
P.B Siddhartha College of arts 
and Science, Vijaywada. 
2000-03 
Academic Distinctions 
Was among the top 3% in the all India entrance exam, GATE 2005. 
Publications 
 Crosslinked acellular saphenous vein for small-diameter vascular graft. Ramesh 
B, Mathapati S, Galla S, Cherian KM, Guhathakurta S. Asian Cardiovascular and 
Thoracic Annals 2013 21: 293. 
 Nanofiber-reinforced biological conduit in cardiac surgery: preliminary report. 
Guhathakurta S, Galla S, Ramesh B, Venugopal JR, Ramakrishna S, Cherian KM. 
Asian Cardiovascular and Thoracic Annals 2011 19: 207. 
 Analytical Study to Evaluate the Extracellular Matrix in Processed Acellular 
Xenografts. Galla S, Santosh Mathapati, Vijaya Nayak, K.M. Cherian, Soma 
Guhathakurta. Indian J Thorac Cardiovasc Surg (2010) 26:132–138. 
 Qualitative and Quantitative Detection of Sodium Deoxycholic Acid in Decellurized 
Tissue. Santosh Mathapati, Galla S, Kavitha Sankaranarayanan, Rama Shanker 
Verma, Kotturathu Mammen Cherian, Soma Guhathakurta. Indian J Thorac 
Cardiovasc Surg (2010) 26:129–131. 
 
Conferences/Symposiums/Workshops Attended (International and National) 
 Satish Galla, Michael Didie, Vijayakumar Muppala, Ralf Dressel, W-H.Zimmermann. 
Immunological properties of parthenogenetic stem cell-derived cardiomyocytes. 
Symposium on cardiovascular regenerative medicine by NIH-NHLBI at Bathesda, 




 Satish Galla, Michael Didie, Vijayakumar Muppala, Ralf Dressel, W-H.Zimmermann. 
Parthenogenetic Stem Cell-derived Cardiomyocytes Express Major 
Histocompatibility Complex-I only after Inflammatory Stimulation. Basic 
Cardiovascular sciences meeting by AHA at Las Vegas, U.S.A. July 14th-17th 2014. 
 Satish Galla, R.Bala Sundari, Sheerinbegam Naser, K.M.Cherian, Soma 
Guhathakurtha. Electrospun polymeric nanofiber reinforced porcine pulmonary 
xenograft as a versatile conduit in cardiovascular surgery. 20th World Congress, 
World society of Cardio-thoracic surgeons Oct 20-23, 2010, Chennai,India. 
 Participated in “International conference on cardiovascular genetics” held on Dec 3
rd 
2008 organized by Frontier lifeline hospital, Chennai.  
 Participated in “Workshop on Nanoscience & Technology for Health Care: Medical 




 Participated in “Recent Trends in Collagen” an international conference held from 
24-25 January 2008 at CLRI, Chennai.  
 Radha C; Ananthakrishnan B; Veerappan S; Satish Galla; K M Cherian; S 
Guhathakurta, Surface characterization of processed natural biological tissue, 
International conference on stem cell, Tissue engineering and regenerative 
medicine, 2007, Frontier Lifeline, Chennai. 
 Radha C; Ananthakrishnan B; Veerappan S; Satish Galla; K M Cherian; S 
Guhathakurta, Validation of Tissue engineered products: The Frontier Lifeline 
experience, International conference on stem cell, Tissue engineering and 
regenerative medicine, 2007, Frontier Lifeline, Chennai. 
 Participated in DBT sponsored workshop on “Industrial Biotechnology-Taking Ideas 




 Implantation of cardiomyocytes under the kidney capsule of mice.  
 Teratoma assays in mice. 
 Isolation of cardiomyocytes from neonatal mice hearts. 
 Langendorff heart perfusion in mice. 
 Isolation of splenocytes and T lymphocytes from mice. 
 
Animal Handling: 
 IP injections in mice and rats  
 Blood sampling techniques from mice and rats 
 Tail vein injections in mice and rats  






 Parthenogenetic and embryonic murine stem cell culture, generation of stable 
cell lines. 
 Differentiation of stem cell into cardiomyocytes. 
 Immune cell proliferation assays and cytotoxicity assays.  
 T lymphocyte culture.  
 Preparation of engineered heart muscle. 
 
Microscopic techniques: 
 Fluorescent microscopy  
 Confocal microscopy 
 2 photon imaging techniques 
 
Other Techniques: 
 Flow cytometry (FACS Diva) 
 Electrospinning of nanofibers  
 Immunohistochemistry / Immunofluorescence 
 Universal tensile testing machine 
 Organ bath setup to study the contractile properties of engineered heart muscle,  
 PCR, qPCR  




 Was involved in the teaching of the course “P.G Diploma in stem cell technology 
and tissue engineering” from Madras University, Chennai. 
 
 Supervised 2 Bachelors and one medicine student for their thesis at Institute of 








 English, Basic German language (A2 level). 
 
